FILE 'HOME' ENTERED AT 11:00:15 ON 29 JAN 2008

=> file polymer biosis embase medline
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'APOLLIT' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (c) 2008 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 11:00:37 ON 29 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (c) 2008 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 11:00:37 ON 29 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 11:00:37 ON 29 JAN 2008
Compendex Compilation and Indexing (C) 2008
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE 'NTIS' ENTERED AT 11:00:37 ON 29 JAN 2008
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2008)

FILE 'PASCAL' ENTERED AT 11:00:37 ON 29 JAN 2008
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2008 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 11:00:37 ON 29 JAN 2008
Copyright (c) 2008 The Thomson Corporation

```
FILE 'TEXTILETECH' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 11:00:37 ON 29 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 11:00:37 ON 29 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:00:37 ON 29 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'WPINDEX' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'WSCA' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 PAINT RESEARCH

FILE 'WTEXTILES' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:00:37 ON 29 JAN 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:00:37 ON 29 JAN 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 11:00:37 ON 29 JAN 2008

=> s alginate
L1      162242 ALGINATE

=> s l1 and tissue
L2       45390 L1 AND TISSUE

=> s l2 and (augment? or volume)
  24 FILES SEARCHED...
L3       28965 L2 AND (AUGMENT? OR VOLUME)

=> s l3 and increas?
  16 FILES SEARCHED...
L4       26601 L3 AND INCREAS?

=> s l4 and (cross(a)link?)
  20 FILES SEARCHED...
L5       11750 L4 AND (CROSS(A) LINK?)

=> s l5 and micropartic?
L6        2611 L5 AND MICROPARTIC?

=> s l6 and (calcium or barium)
L7        2357 L6 AND (CALCIUM OR BARIUM)

=> s l7 and (skin or muscle or sphincter)
L8        2094 L7 AND (SKIN OR MUSCLE OR SPHINCTER)
```

```
=> s l8 and (EDTA or citrate)
L9        1794 L8 AND (EDTA OR CITRATE)

=> s l9 and gel
L10       1767 L9 AND GEL

=> s l9 and hydrogel
L11        800 L9 AND HYDROGEL

=> s l11 and (subcutaneous(s)injection)
  18 FILES SEARCHED...
L12        501 L11 AND (SUBCUTANEOUS(S) INJECTION)

=> s l12 and (adhesion(s)peptide)
  12 FILES SEARCHED...
L13        133 L12 AND (ADHESION(S) PEPTIDE)

=> s l12 and (antibiotic or streptomycin)
L14        421 L12 AND (ANTIBIOTIC OR STREPTOMYCIN)

=> s l14 and (engineer? or replacement)
L15        400 L14 AND (ENGINEER? OR REPLACEMENT)

=> s l15 and adhesion
L16        333 L15 AND ADHESION

=> s l16 and uron?
L17         21 L16 AND URON?

=> dis l17 1-21 bib abs

L17  ANSWER 1 OF 21  USPATFULL on STN
AN     2007:4817  USPATFULL <<LOGINID::20080129>>
TI     2-O sulfatase compositions and methods of hydrolyzing therewith
IN     Sasisekharan, Ram, Bedford, MA, UNITED STATES
       Myette, James, Belmont, MA, UNITED STATES
       Shriver, Zachary, Boston, MA, UNITED STATES
       Venkataraman, Ganesh, Bedford, MA, UNITED STATES
PA     Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
       (U.S. corporation)
PI     US 2007004012       A1  20070104
       US 7247445          B2  20070724
AI     US 2006-432824      A1  20060511 (11)
RLI    Division of Ser. No. US 2004-753761, filed on 7 Jan 2004, PENDING
PRAI   JP 2003-271653      20030707
       US 2003-438810P     20030108 (60)
DT     Utility
FS     APPLICATION
LREP   WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA,
600 ATLANTIC AVENUE,
       BOSTON, MA, 02210-2206, US
CLMN   Number of Claims: 5
ECL    Exemplary Claim: 1
DRWN   20 Drawing Page(s)
LN.CNT 3939
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The invention relates to 2-O sulfatase and uses thereof. In particular,
       the invention relates to recombinantly produced 2-O sulfatase,
       functional variants and nucleic acid molecules that encode these
       molecules. The invention also provides methods of using 2-O sulfatase
```

for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 2 OF 21 USPATFULL on STN
AN 2006:340892 USPATFULL <<LOGINID::20080129>>
TI 2-O sulfatase compositions and methods of degradation therewith
IN Sasisekharan, Ram, Bedford, MA, UNITED STATES
Myette, James, Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2006292673 A1 20061228
AI US 2006-433340 A1 20060511 (11)
RLI Division of Ser. No. US 2004-753761, filed on 7 Jan 2004, PENDING
PRAI JP 2003-271653 20030707
US 2003-438810P 20030108 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 4046
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 3 OF 21 USPATFULL on STN
AN 2006:340874 USPATFULL <<LOGINID::20080129>>
TI 2-O sulfatase compositions and methods of analyzing therewith
IN Sasisekharan, Ram, Bedford, MA, UNITED STATES
Myette, James, Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2006292655 A1 20061228
AI US 2006-433228 A1 20060511 (11)

RLI Division of Ser. No. US 2004-753761, filed on 7 Jan 2004, PENDING
PRAI JP 2003-271653 20030707
US 2003-438810P 20030108 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA,
600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 4004
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 21 USPATFULL on STN
AN 2006:340350 USPATFULL <<LOGINID::20080129>>
TI 2-O sulfatase nucleic acid compositions
IN Sasisekharan, Ram, Bedford, MA, UNITED STATES
Myette, James, Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2006292130 A1 20061228
AI US 2006-433224 A1 20060511 (11)
RLI Division of Ser. No. US 2004-753761, filed on 7 Jan 2004, PENDING
PRAI JP 2003-271653 20030707
US 2003-438810P 20030108 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA,
600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 3977
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular

proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 5 OF 21 USPATFULL on STN
AN 2006:215733 USPATFULL <<LOGINID::20080129>>
TI Delta 4,5 glycuronidase nucleic acid compositions
IN Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
McLean, Maitland W., Orkney, UNITED KINGDOM
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2006183891 A1 20060817
AI US 2006-402491 A1 20060411 (11)
RLI Division of Ser. No. US 2003-429921, filed on 5 May 2003, PENDING
PRAI US 2002-377488P 20020503 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to Δ4,5 glycuronidase, related compositions, and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 6 OF 21 USPATFULL on STN
AN 2006:215557 USPATFULL <<LOGINID::20080129>>
TI Compositions of low molecular weight heparin produced with modified heparinase III
IN Liu, Dongfang, Yorktown Heights, NY, UNITED STATES
Pojasek, Kevin, Cambridge, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Holley, Kristine, Boston, MA, UNITED STATES
El-Shabrawi, Yosuf, Graz, AUSTRIA
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2006183713 A1 20060817
AI US 2006-406215 A1 20060418 (11)
RLI Division of Ser. No. US 2002-291337, filed on 8 Nov 2002, PENDING
Division of Ser. No. US 2001-802285, filed on 8 Mar 2001, GRANTED, Pat. No. US 6869789
PRAI US 2000-187846P 20000308 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1

DRWN 17 Drawing Page(s)
LN.CNT 3014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 7 OF 21 USPATFULL on STN
AN 2006:214581 USPATFULL <<LOGINID::20080129>>
TI Methods for preparing low molecular weight heparin with modified heparinase III
IN Liu, Dongfang, Yorktown Heights, NY, UNITED STATES
Pojasek, Kevin, Cambridge, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Holley, Kristine, Boston, MA, UNITED STATES
El-Shabrawi, Yosuf, Graz, AUSTRIA
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2006182734 A1 20060817
AI US 2006-406214 A1 20060418 (11)
RLI Division of Ser. No. US 2002-291337, filed on 8 Nov 2002, PENDING
Division of Ser. No. US 2001-802285, filed on 8 Mar 2001, GRANTED, Pat. No. US 6869789
PRAI US 2000-187846P 20000308 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA,
600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2988
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 8 OF 21 USPATFULL on STN
AN 2006:208914 USPATFULL <<LOGINID::20080129>>
TI Delta 4,5 glycuronidase and methods of cleaving therewith
IN Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES

Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
McLean, Maitland W., Orkney, UNITED KINGDOM
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 2006177911 A1 20060810
AI US 2006-403096 A1 20060411 (11)
RLI Division of Ser. No. US 2003-429921, filed on 5 May 2003, PENDING
PRAI US 2002-377488P 20020503 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA,
600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to Δ4,5 glycuronidase, related compositions,
and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 9 OF 21 USPATFULL on STN
AN 2006:208913 USPATFULL <<LOGINID::20080129>>
TI Delta 4,5 glycuronidase and methods of hydrolyzing therewith
IN Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
McLean, Maitland W., Orkney, UNITED KINGDOM
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 2006177910 A1 20060810
AI US 2006-402542 A1 20060411 (11)
RLI Division of Ser. No. US 2003-429921, filed on 5 May 2003, PENDING
PRAI US 2002-377488P 20020503 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA,
600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to Δ4,5 glycuronidase, related compositions,
and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 10 OF 21 USPATFULL on STN
AN 2006:208888 USPATFULL <<LOGINID::20080129>>
TI Delta 4,5 glycuronidase and methods of analyzing therewith
IN Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
McLean, Maitland W., Orkney, UNITED KINGDOM

PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 2006177885 A1 20060810
AI US 2006-402543 A1 20060411 (11)
RLI Division of Ser. No. US 2003-429921, filed on 5 May 2003, PENDING
PRAI US 2002-377488P 20020503 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA,
600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to Δ4,5 glycuronidase, related compositions, and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 21 USPATFULL on STN
AN 2006:79937 USPATFULL <<LOGINID::20080129>>
TI Heparinase III and methods of specifically cleaving therewith
IN Liu, Dongfang, Yorktown Heights, NY, UNITED STATES
Pojasek, Kevin, Cambridge, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Holley, Kristine, Boston, MA, UNITED STATES
El-Shabrawi, Yosuf, Graz, AUSTRIA
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 2006067928 A1 20060330
AI US 2005-187571 A1 20050722 (11)
RLI Division of Ser. No. US 2002-291337, filed on 8 Nov 2002, PENDING
Division of Ser. No. US 2001-802285, filed on 8 Mar 2001, GRANTED, Pat. No. US 6869789
PRAI US 2000-187846P 20000308 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA,
600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2211, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2993
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis , etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 12 OF 21 USPATFULL on STN
AN 2005:268086 USPATFULL <<LOGINID::20080129>>
TI Heparinase III HLGAG fragments and uses thereof
IN Liu, Dongfang, Westborough, MA, UNITED STATES
Pojasek, Kevin, Boston, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Holley, Kristine, Boston, MA, UNITED STATES
El-Shabrawi, Yosuf, Graz, AUSTRIA
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Lincoln, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES, 02139 (U.S. corporation)
PI US 2005233402 A1 20051020
AI US 2004-967067 A1 20041014 (10)
RLI Division of Ser. No. US 2002-291337, filed on 8 Nov 2002, PENDING
Division of Ser. No. US 2001-802285, filed on 8 Mar 2001, GRANTED, Pat. No. US 6869789
PRAI US 2000-187846P 20000308 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2211, US
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 3112
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 13 OF 21 USPATFULL on STN
AN 2005:138619 USPATFULL <<LOGINID::20080129>>
TI Heterocyclic compounds and methods of making and using thereof
IN Rao, Yeleswarapu Koteswar, Hyderabad, INDIA
Pal, Manojit, Hyderabad, INDIA
Sharma, Vedula Manohar, Hyderabad, INDIA
Venkateswarlu, Akella, Hyderabad, INDIA
Pillarisetti, Ram, Norcross, GA, UNITED STATES
PI US 2005119269 A1 20050602
AI US 2004-976284 A1 20041028 (10)
PRAI IN 2003-8612003 20031028
US 2004-610163P 20040915 (60)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA,
30357-0037, US
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13564

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I), and methods and/or compositions comprising compounds that are effective in modulating inflammatory responses, such as those resulting from AGE and glycated protein accumulation are provided. Methods and/or compositions comprising compounds that are effective in modulating smooth muscle cell proliferation and the diseases or conditions related thereto are also provided. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 14 OF 21 USPATFULL on STN
AN 2005:43648 USPATFULL <<LOGINID::20080129>>
TI 2-O sulfatase compositions and related methods
IN Sasisekharan, Ram, Lincoln, MA, UNITED STATES
Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Waltham, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA (U.S. corporation)
PI US 2005037376 A1 20050217
US 7270815 B2 20070918
AI US 2004-753761 A1 20040107 (10)
PRAI JP 2003-271653 20030707
US 2003-438810P 20030108 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA,
600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2211
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 4010
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 15 OF 21 USPATFULL on STN
AN 2004:120066 USPATFULL <<LOGINID::20080129>>
TI Delta 4, 5 glycuronidase and uses thereof
IN Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Cambridge, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Cambridge, MA, UNITED STATES
McLean, Maitland W., Orkney, UNITED KINGDOM
PI US 2004091471 A1 20040513
US 2005214276 A9 20050929
AI US 2003-429921 A1 20030505 (10)
PRAI US 2002-377488P 20020503 (60)

DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA,
600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2211
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2709
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to Δ4,5 glycuronidase, related compositions,
and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 16 OF 21 USPATFULL on STN
AN 2003:145884 USPATFULL <<LOGINID::20080129>>
TI Heparinase III and uses thereof
IN Liu, Dongfang, Framingham, MA, UNITED STATES
Pojasek, Kevin, Cambridge, MA, UNITED STATES
Shriver, Zachary, Cambridge, MA, UNITED STATES
Holley, Kristine, Boston, MA, UNITED STATES
El-Shabrawi, Yosuf, Cambridge, MA, UNITED STATES
Venkataraman, Ganesh, Woburn, MA, UNITED STATES
Sasisekharan, Ram, Cambridge, MA, UNITED STATES
PI US 2003099628 A1 20030529
AI US 2002-291337 A1 20021108 (10)
RLI Division of Ser. No. US 2001-802285, filed on 8 Mar 2001, PENDING
PRAI US 2000-187846P 20000308 (60)
DT Utility
FS APPLICATION
LREP Helen C. Lockhart, Wolf, Greenfield
& Sacks, P.C., 600 Atlantic Avenue,
Boston, MA, 02210
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 3157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heparinase III and mutants thereof. Modified
forms of heparinase II having reduced enzymatic activity which are
useful for a variety of purposes, including sequencing of heparin-like
glycosaminoglycans (HLGAGs), removing active heparan sulfate from a
solution, inhibition of angiogenesis, etc. have been discovered
according to the invention. The invention in other aspects relates to
methods of treating cancer and inhibiting tumor cell growth and/or
metastasis using heparinase III, or products produced by enzymatic
cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 17 OF 21 USPATFULL on STN
AN 2002:227642 USPATFULL <<LOGINID::20080129>>
TI Heparinase III and uses thereof
IN Liu, Dongfang, Framingham, MA, UNITED STATES
Pojasek, Kevin, Cambridge, MA, UNITED STATES
Shriver, Zachary, Cambridge, MA, UNITED STATES
Holley, Kristine, Boston, MA, UNITED STATES
El-Shabrawi, Yosuf, Graz, AUSTRIA
Venkataraman, Ganesh, Wallham, MA, UNITED STATES
Sasisekharan, Ram, Cambridge, MA, UNITED STATES

PI US 2002122793 A1 20020905
    US 6869789 B2 20050322
AI US 2001-802285 A1 20010308 (9)
PRAI US 2000-187846P 20000308 (60)
DT Utility
FS APPLICATION
LREP Helen C. Lockhart, c/o Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 3154
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 18 OF 21 USPAT2 on STN
AN 2007:4817 USPAT2 <<LOGINID::20080129>>
TI 2-O sulfatase compositions and methods of hydrolyzing therewith
IN Sasisekharan, Ram, Bedford, MA, UNITED STATES
    Myette, James R., Waltham, MA, UNITED STATES
    Shriver, Zachary, Cambridge, MA, UNITED STATES
    Venkataraman, Ganesh, Bedford, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 7247445 B2 20070724
AI US 2006-432824 20060511 (11)
RLI Continuation of Ser. No. US 2004-753761, filed on 7 Jan 2004, PENDING
PRAI JP 2003-271653 20030707
    US 2003-438810P 20030108 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saidha, Tekchand
LREP Wolf, Greenfield & Sacks, P.C.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 5125
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 19 OF 21 USPAT2 on STN
AN 2005:43648 USPAT2 <<LOGINID::20080129>>
TI 2-O sulfatase compositions and related methods
IN Sasisekharan, Ram, Lincoln, MA, UNITED STATES
Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Waltham, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 7270815 B2 20070918
AI US 2004-753761 20040107 (10)
PRAI JP 2003-271653 20030707
US 2003-438810P 20030108 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saidha, Tekchand
LREP Wolf, Greenfield & Sacks, P.C.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 4158
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 20 OF 21 USPAT2 on STN
AN 2004:120066 USPAT2 <<LOGINID::20080129>>
TI Delta 4, 5 glycuronidase and uses thereof
IN Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Cambridge, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Cambridge, MA, UNITED STATES
McLean, Maitland W., Orkney, UNITED KINGDOM
PI US 2005214276 A9 20050929
AI US 2003-429921 A1 20030505 (10)
PRAI US 2002-377488P 20020503 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA,
600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2211, US
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2696
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to Δ4,5 glycuronidase, related compositions, and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 21 OF 21 USPAT2 on STN
AN 2002:227642 USPAT2 <<LOGINID::20080129>>
TI Heparinase III and uses thereof
IN Liu, Dongfang, Westborough, MA, United States
Pojasek, Kevin, Boston, MA, United States
Shriver, Zachary, Boston, MA, United States
Holley, Kristine, Boston, MA, United States
El-Shabrawi, Yosuf, Graz, AUSTRIA
Venkataraman, Ganesh, Waltham, MA, United States
Sasisekharan, Ram, Lincoln, MA, United States
PA Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
PI US 6869789 B2 20050322
AI US 2001-802285 20010308 (9)
PRAI US 2000-187846P 20000308 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Swope, Sheridan L.
LREP Wolf, Greenfield & Sacks, P.C.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 3359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis l13 1-133 bib abs

L13 ANSWER 1 OF 133 USPATFULL on STN
AN 2008:5040 USPATFULL <<LOGINID::20080129>>
TI METHODS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES FOR TREATING AND PREVENTING OBESITY
IN Quay, Steven C., Woodinville, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2008004218 A1 20080103
AI US 2006-563587 A1 20061127 (11)
RLI Division of Ser. No. US 2004-869649, filed on 16 Jun 2004, GRANTED, Pat. No. US 7186692 Continuation-in-part of Ser. No. US 2003-745069, filed on 23 Dec 2003, GRANTED, Pat. No. US 7186691 Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, GRANTED, Pat. No. US 7166575
PRAI US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)

US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 5451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for treating obesity, inducing weight-loss, or inducing satiety in a mammal comprising administering intranasally to the mammal a therapeutically effective amount of a pharmaceutical composition comprising PYY(3-36), a phosphatidylcholine or diglyceride, and a cyclodextrin, wherein the phosphatidylcholine or diglyceride and the cyclodextrin are present in an amount sufficient to enhance epithelial permeation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 133 USPATFULL on STN
AN 2007:334990 USPATFULL <<LOGINID::20080129>>
TI HUMAN CDNAS AND PROTEINS AND USES THEREOF
IN BEJANIN, STEPHANE, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PI US 2007292885 A1 20071220
AI US 2007-831468 A1 20070731 (11)
RLI Continuation of Ser. No. US 2004-838854, filed on 3 May 2004, GRANTED, Pat. No. US 7291495 Division of Ser. No. US 2001-489, filed on 14 Nov 2001, GRANTED, Pat. No. US 6794363 Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, GRANTED, Pat. No. US 7074901
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX
142950, GAINESVILLE, FL, 32614-2950, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 26802
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides polynucleotides and polypeptides encoding an isolated amyloid inhibitor protein (APIP) and compositions thereof. The polypeptides of the subject invention can be used to inhibit the catabolism or sequential cleavage of amyloid beta precursor protein (APP) by sequential cleavage of APP by beta secretase and gamma secretase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 133 USPATFULL on STN
AN 2007:315688 USPATFULL <<LOGINID::20080129>>
TI COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF PEPTIDE YY FOR TREATING OBESITY
IN Quay, Steven C., Seattle, WA, UNITED STATES

PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2007275893 A1 20071129
AI US 2006-561331 A1 20061117 (11)
RLI Division of Ser. No. US 2002-322266, filed on 17 Dec 2002, GRANTED, Pat. No. US 7166575
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12004
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions comprising PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 133 USPATFULL on STN
AN 2007:302266 USPATFULL <<LOGINID::20080129>>
TI Methods of Therapy and Diagnosis Using Targeting of Cells that Express Killer Cell Immunoglobulin like Receptor like Proteins
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
PA NUVELO, INC., San Carlos, CA, UNITED STATES, 94070 (U.S. corporation)
PI US 2007264261 A1 20071115
AI US 2007-766911 A1 20070622 (11)
RLI Division of Ser. No. US 2004-962127, filed on 8 Oct 2004, PENDING Continuation-in-part of Ser. No. WO 2004-US11171, filed on 13 Apr 2004, PENDING Continuation-in-part of Ser. No. US 2003-727012, filed on 2 Dec 2003, ABANDONED Continuation-in-part of Ser. No. US 2003-414539, filed on 14 Apr 2003, ABANDONED
DT Utility
FS APPLICATION
LREP NUVELO, INC, 201 INDUSTRIAL ROAD, SUITE 310, SAN CARLOS, CA, 94070, US
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 7979
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including various types of cancer cells, express KIRHy proteins. Targeting using KIRHy polypeptides, nucleic acids encoding for KIRHy polypeptides and anti-KIRHy antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy protein. Methods of therapy and diagnosis of disorders associated with KIRHy protein-expressing cells, such as acute myelogenous leukemia (AML), are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 133 USPATFULL on STN
AN 2007:265460 USPATFULL <<LOGINID::20080129>>
TI INTRANASAL PYY FORMULATIONS WITH IMPROVED TRANSMUCOSAL PHARMACOKINETICS
IN Costantino, Henry R., Woodinville, WA, UNITED STATES
Kleppe, Mary S., Snohomish, WA, UNITED STATES
Cohen, Annemarie Stoudt, Kirkland, WA, UNITED STATES

Sileno, Anthony P., Brookhaven Hamlet, NY, UNITED STATES
PA Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)
PI US 2007232537 A1 20071004
AI US 2006-613109 A1 20061219 (11)
PRAI US 2005-751598P 20051219 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 3512
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB What is described is an aqueous Y2 receptor-binding peptide formulation for enhanced intranasal delivery of a Y2 receptor-binding peptide, comprising said Y2 receptor-binding peptide, a buffer salt, and having a pH between about 3.0 and about 6.0, wherein said buffer salt comprises a net single ionogenic moiety with a pK.sub.a within two pH units of the pH of the formulation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 133 USPATFULL on STN
AN 2007:243758 USPATFULL <<LOGINID::20080129>>
TI PEPTIDE YY FORMULATIONS HAVING INCREASED STABILITY AND RESISTANCE TO MICROBIAL AGENTS
IN Costantino, Henry R., Woodinville, WA, UNITED STATES
Kleppe, Mary S., Snohomish, WA, UNITED STATES
Cohen, Annemarie Stoudt, Kirkland, WA, UNITED STATES
PI US 2007213270 A1 20070913
AI US 2005-570223 A1 20050616 (11)
WO 2005-US21377 20050616
20061207 PCT 371 date
PRAI US 2004-580329P 20040616 (60)
US 2004-580310P 20040616 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 79
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 4216
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY (PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) wherein the formulations have increased resistance to microbial contamination and is comprised of a Y2 receptor-binding peptide, water, a cyclodextrin and sodium benzoate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 133 USPATFULL on STN
AN 2007:225337 USPATFULL <<LOGINID::20080129>>
TI COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES
IN Quay, Steven C., Woodinville, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES

Kleppe, Mary S., Snohomish, WA, UNITED STATES
MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2007197437 A1 20070823
AI US 2006-561825 A1 20061120 (11)
RLI Division of Ser. No. US 2003-745069, filed on 23 Dec 2003, GRANTED, Pat. No. US 7186691 Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, GRANTED, Pat. No. US 7166575
PRAI WO 2003-US40538 20031217
US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 5390
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions comprising a PYY peptide, a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 133 USPATFULL on STN
AN 2007:224799 USPATFULL <<LOGINID::20080129>>
TI POLYNUCLEOTIDES ENCODING A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR SPLICE VARIANT, HGPRBMY29SV2
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Hawken, Donald R., Lawrenceville, NJ, UNITED STATES
PI US 2007196897 A1 20070823
US 7276354 B2 20071002
AI US 2005-71761 A1 20050303 (11)
RLI Division of Ser. No. US 2002-120604, filed on 11 Apr 2002, GRANTED, Pat. No. US 7049096
PRAI US 2001-283145P 20010411 (60)
US 2001-283161P 20010411 (60)
US 2001-288468P 20010503 (60)
US 2001-300619P 20010625 (60)
DT Utility
FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1-20
DRWN 36 Drawing Page(s)
LN.CNT 19968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants

of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 133 USPATFULL on STN
AN 2007:211227 USPATFULL <<LOGINID::20080129>>
TI ENHANCED MUCOSAL ADMINISTRATION OF NEUROPROTECTIVE PEPTIDES
IN Costantino, Henry R., Woodinville, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)
PI US 2007185035 A1 20070809
AI US 2006-614534 A1 20061221 (11)
PRAI US 2005-753968P 20051223 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3218
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation for intranasal delivery of a neuroprotective peptide, comprising an aqueous mixture of a peptide having the sequence NAPVSIPQ or a pharmaceutically acceptable salt thereof, a solubilizing agent, a chelator, and a surface active agent. The formulation can contain a peptide salt or mucosal delivery-enhancing agent which increases the amount of neuroprotective peptide reaching the therapeutic target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 133 USPATFULL on STN
AN 2007:203434 USPATFULL <<LOGINID::20080129>>
TI Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunoglobulin folds, BGS2, 3 and 4 and variants thereof
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Krystek, Stanley R. JR., Ringoes, NJ, UNITED STATES
Lee, Liana, San Francisco, CA, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Cheng, Janet D., Seattle, WA, UNITED STATES
PA Bristol-Myers Squibb Company (U.S. corporation)
PI US 2007178088 A1 20070802
AI US 2007-726220 A1 20070321 (11)
RLI Division of Ser. No. US 2002-193477, filed on 11 Jul 2002, GRANTED, Pat. No. US 7223558
PRAI US 2001-304888P 20010711 (60)
US 2002-372147P 20020412 (60)
DT Utility
FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX

4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 18750
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding BGS-2, 3, and 4 polypeptides, fragments and homologues thereof Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-2, 3, and 4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 133 USPATFULL on STN
AN 2007:184570 USPATFULL <<LOGINID::20080129>>
TI A DEVICE FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES
IN Quay, Steven C., Woodinville, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
Kleppe, Mary S., Snohomish, WA, UNITED STATES
MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2007161563 A1 20070712
AI US 2006-562913 A1 20061122 (11)
RLI Division of Ser. No. US 2004-780325, filed on 17 Feb 2004, PENDING Continuation of Ser. No. US 2003-745069, filed on 23 Dec 2003, GRANTED, Pat. No. US 7186691 Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, GRANTED, Pat. No. US 7166575
PRAI WO 2003-US40538 20031217
US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 5557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical device comprising a composition comprising an aqueous solution of PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation, and wherein the composition is present in a container; and an actuator fluidly connected to the container, wherein the actuator has a tip which defines a passage through which the solution is ejected to produce a spray of the solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 12 OF 133 USPATFULL on STN
AN 2007:154119 USPATFULL <<LOGINID::20080129>>
TI Polymer particles for delivery of macromolecules and methods of use
IN Turnell, William D., San Diego, CA, UNITED STATES
Landis, Geoffrey C., Carlsbad, CA, UNITED STATES
Gomurashvili, Zaza D., La Jolla, CA, UNITED STATES
Li, Hong, San Diego, CA, UNITED STATES
DeFife, Kristin, San Diego, CA, UNITED STATES
Vassilev, Vassil P., San Diego, CA, UNITED STATES
Yuan, Yumin, San Diego, CA, UNITED STATES
PA MediVas, LLC, San Diego, CA, UNITED STATES, 92121 (U.S. corporation)
PI US 2007134332 A1 20070614
AI US 2006-603660 A1 20061121 (11)
PRAI US 2006-796067P 20060427 (60)
US 2005-738769P 20051121 (60)
DT Utility
FS APPLICATION
LREP DLA PIPER US LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133, US
CLMN Number of Claims: 71
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 3498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides biodegradable polymer particle delivery compositions for delivery of macromolecular biologics, for example in crystal form, based on polymers, such as polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers, which contain amino acids in the polymer. The polymer particle delivery compositions can be formulated either as a liquid dispersion or a lyophilized powder of polymer particles containing bound water molecules with the macromolecular biologics, for example insulin, dispersed in the particles. Bioactive agents, such as drugs, polypeptides, and polynucleotides can also be delivered by using particles sized for local, oral, mucosal or circulatory delivery. Methods of delivering a macromolecular biologic with substantial native activity to a subject, for example orally, are also included.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 13 OF 133 USPATFULL on STN
AN 2007:148203 USPATFULL <<LOGINID::20080129>>
TI COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE
IN Quay, Steven C., Seattle, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
Kleppe, Mary S., Snohomish, WA, UNITED STATES
MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2007129299 A1 20070607
AI US 2006-467509 A1 20060825 (11)
RLI Division of Ser. No. US 2004-768288, filed on 30 Jan 2004, GRANTED, Pat. No. US 7157426 Continuation of Ser. No. US 2003-745069, filed on 23 Dec 2003, GRANTED, Pat. No. US 7186691 Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, GRANTED, Pat. No. US 7166575
PRAI WO 2003-US40538 20031217
US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility

FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 5937
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions are described comprising PYY(3-36) (SEQ ID NO: 2), a solubilizing agent, a lipid, a polyol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 14 OF 133 USPATFULL on STN
AN 2007:140890 USPATFULL <<LOGINID::20080129>>
TI Rhamnose-inducible expression systems and methods
IN Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2007122881 A1 20070531
AI US 2006-580095 A1 20061011 (11)
RLI Division of Ser. No. US 2002-156902, filed on 28 May 2002, GRANTED, Pat. No. US 7183105 Division of Ser. No. US 2002-154951, filed on 24 May 2002, ABANDONED
PRAI US 2001-293566P 20010524 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614, US
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 27475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Rhamnose-inducible expression constructs are described. The expression constructs may be either episomal or chromosomal and may include at least one rhamnose-inducible regulatory element expressing a regulatory protein and at least one promoter that is inducible by the regulatory protein. An open reading frame expressing a protein of interest may be placed under control of the promoter. Also described are optimized Shine-Dalgarno sequences for use with the promoter.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 15 OF 133 USPATFULL on STN
AN 2007:55442 USPATFULL <<LOGINID::20080129>>
TI Self-assembled endovascular structures
IN Helmus, Michael N., Worcester, MA, UNITED STATES
PI US 2007048383 A1 20070301
AI US 2005-211809 A1 20050825 (11)
DT Utility
FS APPLICATION
LREP MAYER & WILLIAMS PC, 251 NORTH AVENUE WEST, 2ND FLOOR, WESTFIELD, NJ,
07090, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to the formation of structures in situ

through the principles of ligand binding. These structures are efficacious, for example, for tissue repair as well as for short- and long-term disease and condition management. According to one aspect of the invention, an injectable composition comprising self-assembling nanoparticles is provided. The self-assembling nanoparticles include: (a) a nanoparticle portion, (b) tissue binding ligands attached to the nanoparticle portion, which cause preferential binding and accumulation of the nanoparticles at one or more targeted tissue locations upon injection of the composition into the body, and (c) first and second interparticle binding ligands attached to the nanoparticle portion, which cause interparticle binding upon injection of the composition into the body.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 16 OF 133 USPATFULL on STN
AN 2007:36348 USPATFULL <<LOGINID::20080129>>
TI Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Ringoes, NJ, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
PA Bristol-Myers Squibb Company (U.S. corporation)
PI US 2007031888 A1 20070208
AI US 2006-582264 A1 20061017 (11)
RLI Division of Ser. No. US 2004-882761, filed on 1 Jul 2004, PENDING
Division of Ser. No. US 2001-29347, filed on 20 Dec 2001, GRANTED, Pat. No. US 6858407
PRAI US 2000-257774P 20001222 (60)
DT Utility
FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1-23
DRWN 16 Drawing Page(s)
LN.CNT 14307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 17 OF 133 USPATFULL on STN
AN 2006:333477 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for the treatment of burns and sepsis
IN Berenson, Ronald J., Mercer Island, WA, UNITED STATES
Bonyhadi, Mark, Issaquah, WA, UNITED STATES
PA XCYTE Therapies, Inc., Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2006286089 A1 20061221
AI US 2006-400071 A1 20060407 (11)
PRAI US 2005-669816P 20050408 (60)
DT Utility

FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 5400, SEATTLE, WA, 98104, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 52 Drawing Page(s)
LN.CNT 4133
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to methods for treating burns and sepsis, in particular for treating immune dysfunction associated with burns and sepsis. The present invention also relates to activating and expanding T cells for the treatment of burns and sepsis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 18 OF 133 USPATFULL on STN
AN 2006:301494 USPATFULL <<LOGINID::20080129>>
TI Severe acute respiratory syndrome coronavirus
IN Rappuoli, Rino, Castelnuovo Berardenga, ITALY
Masignani, Vega, Siena, ITALY
Stadler, Konrad, Scharnstein, AUSTRALIA
Gregersen, Jens Peter, Wetter, GERMANY, FEDERAL REPUBLIC OF
Chien, David, Alamo, CA, UNITED STATES
Han, Jang, Lafayette, CA, UNITED STATES
Polo, John M., Danville, CA, UNITED STATES
Weiner, Amy, Fairfield, CA, UNITED STATES
Houghton, Michael, Danville, CA, UNITED STATES
Song, Hyun Chul, Berkeley, CA, UNITED STATES
Seo, Mi-Young, Yongin-si, KOREA, REPUBLIC OF
Donnelly, John, Moraga, CA, UNITED STATES
Klenk, Hans Dieter, Marburg, GERMANY, FEDERAL REPUBLIC OF
Valiante, Nicholas, Fremont, CA, UNITED STATES
PA Chiron Corporation, Emeryville, CA, UNITED STATES (U.S. corporation)
PI US 2006257852 A1 20061116
AI US 2004-822303 A1 20040409 (10)
PRAI US 2003-462218P 20030410 (60)
US 2003-462465P 20030411 (60)
US 2003-462418P 20030412 (60)
US 2003-462748P 20030413 (60)
US 2003-463109P 20030414 (60)
US 2003-463460P 20030415 (60)
US 2003-463668P 20030416 (60)
US 2003-463983P 20030417 (60)
US 2003-463971P 20030418 (60)
US 2003-464899P 20030422 (60)
US 2003-464838P 20030422 (60)
US 2003-465273P 20030423 (60)
US 2003-465535P 20030424 (60)
US 2003-468312P 20030505 (60)
US 2003-473144P 20030522 (60)
US 2003-495024P 20030814 (60)
US 2003-505652P 20030923 (60)
US 2003-510781P 20031011 (60)
US 2003-529464P 20031211 (60)
US 2004-536177P 20040112 (60)
US 2004-560757P 20040407 (60)
DT Utility
FS APPLICATION
LREP Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US
CLMN Number of Claims: 120

ECL Exemplary Claim: 1
DRWN 198 Drawing Page(s)
LN.CNT 30451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 19 OF 133 USPATFULL on STN
AN 2006:247225 USPATFULL <<LOGINID::20080129>>
TI Method of treatment of a metabolic disease using intranasal administration of exendin peptide
IN Quay, Steven C., Seattle, WA, UNITED STATES
Leonard, Alexis Kays, Maple Valley, WA, UNITED STATES
Costantino, Henry R., Woodinville, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2006210614 A1 20060921
AI US 2006-418982 A1 20060504 (11)
RLI Continuation of Ser. No. US 2005-293715, filed on 2 Dec 2005, ABANDONED Continuation-in-part of Ser. No. US 2004-991597, filed on 18 Nov 2004, PENDING
PRAI US 2003-532337P 20031226 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906, US
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for treating metabolic diseases are described for intranasal delivery of an exenatide, comprising an aqueous mixture of exendin, and a delivery enhancer selected from the group consisting of a solubilizer, a chelator, and a surfactant, and the pharmaceutical formulations used therein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 20 OF 133 USPATFULL on STN
AN 2006:215041 USPATFULL <<LOGINID::20080129>>
TI Polynucleotide encoding a novel cysteine protease of the calpain superfamily, CAN-12, and variants thereof
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES
Vaz, Roy J., North Branch, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2006183196 A1 20060817
AI US 2006-407134 A1 20060419 (11)
RLI Division of Ser. No. US 2002-116519, filed on 3 Apr 2002, PENDING
PRAI US 2001-281253P 20010403 (60)

US 2001-288768P 20010504 (60)
US 2001-296180P 20010606 (60)
US 2001-300620P 20010625 (60)
DT Utility
FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1-23
DRWN 27 Drawing Page(s)
LN.CNT 29767
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding CAN-12 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of CAN-12 polypeptides, CAN-12v1 and CAN-12v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel CAN-12, CAN-12v1, and CAN-12v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly neuro- and musculo-degenerative conditions. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 21 OF 133 USPATFULL on STN
AN 2006:174525 USPATFULL <<LOGINID::20080129>>
TI Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas, Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES
Bassolino, Donna A, Hamilton, NJ, UNITED STATES
Cheney, Daniel L., Flemington, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2006147973 A1 20060706
US 7256267 B2 20070814
AI US 2006-329900 A1 20060111 (11)
RLI Division of Ser. No. US 2001-993180, filed on 14 Nov 2001, PENDING
PRAI US 2000-248434P 20001114 (60)
US 2000-257610P 20001221 (60)
US 2001-282745P 20010410 (60)
DT Utility
FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1-52
DRWN 8 Drawing Page(s)
LN.CNT 18514
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various

diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 22 OF 133 USPATFULL on STN
AN 2006:174046 USPATFULL <<LOGINID::20080129>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2006147492 A1 20060706
AI US 2006-343809 A1 20060131 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 56233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 23 OF 133 USPATFULL on STN
AN 2006:136908 USPATFULL <<LOGINID::20080129>>
TI Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
IN Pier, Gerald B., Brookline, MA, UNITED STATES
Kelly-Quintos, Casie Anne, Boston, MA, UNITED STATES
Cavacini, Lisa, Natick, MA, UNITED STATES
Posner, Marshall R., Medfield, MA, UNITED STATES
PA The Brigham and Women's Hospital, Inc., Boston, MA, UNITED STATES (U.S.

corporation)
Beth Israel Deaconess Medical Center, Inc., Boston, MA, UNITED STATES (U.S. corporation)
PI US 2006115486 A1 20060601
AI US 2005-111688 A1 20050421 (11)
PRAI US 2004-564105P 20040421 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 3365
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 24 OF 133 USPATFULL on STN
AN 2006:87024 USPATFULL <<LOGINID::20080129>>
TI Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
IN Quay, Steven C., Seattle, WA, UNITED STATES
Kleppe, Mary S., Snohomish, WA, UNITED STATES
Costantino, Henry R., Woodinville, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2006074025 A1 20060406
AI US 2005-293676 A1 20051202 (11)
RLI Continuation-in-part of Ser. No. US 2004-991597, filed on 18 Nov 2004, PENDING
PRAI US 2003-532337P 20031226 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4017
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB What is described is a pharmaceutical formulation for intranasal delivery of glucagon-like protein-1 (GLP-1), comprising an aqueous mixture of GLP-1, a solubilizing agent, a chelator, and a surface active agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 25 OF 133 USPATFULL on STN

AN 2006:81026 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
IN Costantino, Henry R., Woodinville, WA, UNITED STATES
Herman, Richard E., Redmond, WA, UNITED STATES
Houston, Michael E. JR., Sammamish, WA, UNITED STATES
Johnson, Paul Hickok, Snohomish, WA, UNITED STATES
Rana, Rajsharan K., Woodinville, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2006069021 A1 20060330
AI US 2005-205255 A1 20050815 (11)
PRAI US 2004-601215P 20040813 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3450 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-8906, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 3788
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at inactive forms or parathyroid hormone peptide (PTH) or PTH analogs wherein the inactive forms are activated upon administration into the systemic circulation. Also described is a method of preventing local reaction to a biologically active agent, preparing a formulation comprising said biologically active agent, a solubilizing agent and a surfactant, and administering such formulation by contacting said formulation with a mucosal surface.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 26 OF 133 USPATFULL on STN
AN 2006:15798 USPATFULL <<LOGINID::20080129>>
TI Human phosphatase RET31, and variants thereof
IN Jackson, Donald G., Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Suchard, Suzanne, Wilmington, DE, UNITED STATES
Schieven, Gary, Lawrenceville, NJ, UNITED STATES
Finger, Joshua, San Marcos, CA, UNITED STATES
Todderrud, C. Gordon, Newtown, PA, UNITED STATES
Bassolino, Donna, Hamilton, NJ, UNITED STATES
Krystek, Stanley, Ringoes, NJ, UNITED STATES
Banas, Dana, Hamilton, NJ, UNITED STATES
McAtee, Patrick, Pennington, NJ, UNITED STATES
PI US 2006014180 A1 20060119
AI US 2005-143984 A1 20050602 (11)
RLI Division of Ser. No. US 2001-29345, filed on 20 Dec 2001, PENDING
PRAI US 2000-256868P 20001220 (60)
US 2001-280186P 20010330 (60)
US 2001-287735P 20010501 (60)
US 2001-295848P 20010605 (60)
US 2001-300465P 20010625 (60)
DT Utility
FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1-25
DRWN 67 Drawing Page(s)
LN.CNT 29165
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 27 OF 133 USPATFULL on STN
AN 2006:3492 USPATFULL <<LOGINID::20080129>>
TI Ii-key/antigenic epitope hybrid peptide vaccines
IN Humphreys, Robert, Acton, MA, UNITED STATES
Xu, Minzhen, Northborough, MA, UNITED STATES
PI US 2006002947 A1 20060105
AI US 2005-33039 A1 20050111 (11)
RLI Continuation-in-part of Ser. No. US 2002-245871, filed on 17 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2002-197000, filed on 17 Jul 2002, PENDING Division of Ser. No. US 1999-396813, filed on 14 Sep 1999, GRANTED, Pat. No. US 6432409
DT Utility
FS APPLICATION
LREP KEVIN M. FARRELL, PIERCE ATWOOD, ONE NEW HAMPSHIRE AVENUE, SUTIE 350, PORTSMOUTH, NH, 03801, US
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is an antigen presentation enhancing hybrid polypeptide which includes three elements. The first element is an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity. The second element is a chemical structure covalently linking the N-terminal element described above to the MHC Class II-presented epitope described below. The chemical structure is a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion, the chemical structure being selected from the group consisting of: i) immunologically neutral chemical structures, ii) a MHC Class I epitope or a portion thereof, and/or iii) an antibody-recognized determinant or a portion thereof. Finally, the enhancing antigen presentation enhancing hybrid polypeptide includes a C-terminal element comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 28 OF 133 USPATFULL on STN
AN   2005:323977 USPATFULL <<LOGINID::20080129>>
TI   Compositions and systems for forming crosslinked biomaterials and
       associated methods of preparation and use
IN   Daniloff, George Y., Mountain View, CA, UNITED STATES
       Sehl, Louis C., Redwood City, CA, UNITED STATES
       Trollsas, Olof Mikael, San Jose, CA, UNITED STATES
       Schroeder, Jacqueline, Boulder Creek, CA, UNITED STATES
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
PI   US 2005281883   A1 20051222
AI   US 2005-118088   A1 20050428 (11)
PRAI   US 2004-566569P   20040428 (60)
DT   Utility
FS   APPLICATION
LREP   REED INTELLECTUAL PROPERTY LAW GROUP, 1400 PAGE MILL ROAD, PALO ALTO,
       CA, 94304-1124, US
CLMN   Number of Claims: 349
ECL   Exemplary Claim: 1
DRWN   2 Drawing Page(s)
LN.CNT 8347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   Crosslinkable compositions are provided that readily crosslink in situ
       to provide crosslinked biomaterials. The composition contains at least
       two biocompatible, non-immunogenic components having reactive groups
       thereon, with the functional groups selected so as to enable
       inter-reaction between the components, i.e., crosslinking. In one
       embodiment, a first component has nucleophilic groups and a second
       component has electrophilic groups. Additional components may have
       nucleophilic or electrophilic groups. Methods for preparing and using
       the compositions are also provided as are kits for delivery of the
       compositions. Exemplary uses for the crosslinked compositions include
       tissue augmentation, biologically active agent
       delivery, bioadhesion, and prevention of adhesions following surgery or
       injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 29 OF 133 USPATFULL on STN
AN   2005:260791 USPATFULL <<LOGINID::20080129>>
TI   Methods of therapy and diagnosis using targeting of cells that express
       killer cell immunoglobulin-like receptor-like proteins
IN   Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
       Tang, Y. Tom, San Jose, CA, UNITED STATES
PA   NUVELO, Inc., Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI   US 2005226812   A1 20051013
AI   US 2004-962127   A1 20041008 (10)
RLI   Continuation-in-part of Ser. No. WO 2004-US11171, filed on 13 Apr 2004,
       PENDING Continuation-in-part of Ser. No. US 2003-727012, filed on 2 Dec
       2003, PENDING Continuation-in-part of Ser. No. US 2003-414539, filed on
       14 Apr 2003, ABANDONED
DT   Utility
FS   APPLICATION
LREP   NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US
CLMN   Number of Claims: 47
ECL   Exemplary Claim: 1
DRWN   16 Drawing Page(s)
LN.CNT 6068
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   Certain cells, including various types of cancer cells, express KIRHy

proteins. Targeting using KIRHy polypeptides, nucleic acids encoding for KIRHy polypeptides and anti-KIRHy antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy protein. Methods of therapy and diagnosis of disorders associated with KIRHy protein-expressing cells, such as acute myelogenous leukemia (AML), are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 30 OF 133 USPATFULL on STN
AN 2005:254894 USPATFULL <<LOGINID::20080129>>
TI Molecular interactions in hematopoietic cells
IN Lu, Peter S., Mountain View, CA, UNITED STATES
Rabinowitz, Joshua D., Mountain View, CA, UNITED STATES
Schweizer, Johannes, Mountain View, CA, UNITED STATES
PA Arbor Vita Corporation, Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 2005221388 A1 20051006
AI US 2005-131042 A1 20050516 (11)
RLI Continuation of Ser. No. US 2000-688017, filed on 13 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-570118, filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-570364, filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-569525, filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-547276, filed on 11 Apr 2000, ABANDONED
PRAI US 2000-196460P 20000411 (60)
US 2000-196528P 20000411 (60)
US 2000-196527P 20000411 (60)
US 2000-196267P 20000411 (60)
US 2000-182296P 20000214 (60)
US 2000-176195P 20000114 (60)
US 1999-170453P 19991213 (60)
US 1999-162498P 19991029 (60)
US 1999-160860P 19991021 (60)
US 1999-134118P 19990514 (60)
US 1999-134117P 19990514 (60)
US 1999-134114P 19990514 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1-30
DRWN 14 Drawing Page(s)
LN.CNT 7797
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 31 OF 133 USPATFULL on STN
AN 2005:247674 USPATFULL <<LOGINID::20080129>>
TI Molecular interactions in hematopoietic cells
IN Lu, Peter S., Mountain View, CA, UNITED STATES
Rabinowitz, Joshua D., Mountain View, CA, UNITED STATES
Schweizer, Johannes, Mountain View, CA, UNITED STATES
PA Arbor Vita Corporation, Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 2005214869 A1 20050929

AI US 2005-131054 A1 20050516 (11)
RLI Continuation of Ser. No. US 2000-688017, filed on 13 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-570118, filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-570364, filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-569525, filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-547276, filed on 11 Apr 2000, ABANDONED
PRAI US 2000-196460P 20000411 (60)
US 2000-196528P 20000411 (60)
US 2000-196527P 20000411 (60)
US 2000-196267P 20000411 (60)
US 2000-182296P 20000214 (60)
US 2000-176195P 20000114 (60)
US 1999-170453P 19991213 (60)
US 1999-162498P 19991029 (60)
US 1999-160860P 19991021 (60)
US 1999-134118P 19990514 (60)
US 1999-134117P 19990514 (60)
US 1999-134114P 19990514 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1-30
DRWN 14 Drawing Page(s)
LN.CNT 7785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 32 OF 133 USPATFULL on STN
AN 2005:240498 USPATFULL <<LOGINID::20080129>>
TI Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like protein
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
Zhou, Ping, Cupertino, CA, UNITED STATES
Asundi, Vinod, Foster City, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Drmanac, Radoje T., Los Altos Hills, CA, UNITED STATES
PA NUVELO, Inc., Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 2005208498 A1 20050922
AI US 2003-727012 A1 20031202 (10)
RLI Continuation-in-part of Ser. No. US 2003-414539, filed on 14 Apr 2003, ABANDONED Continuation-in-part of Ser. No. US 2000-631451, filed on 3 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-491404, filed on 25 Jan 2000, ABANDONED
PRAI WO 2001-US2623 20010125
WO 2001-US2687 20010125
DT Utility
FS APPLICATION
LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 4892

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including types of cancer cells such as KIRHy1, are capable of expressing KIRHy1 mRNA. Targeting using KIRHy1 polypeptides, nucleic acids encoding for KIRHy1 polypeptides and anti-KIRHy1 antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy1 protein. Methods of therapy and diagnosis of disorders associated with KIRHy1 protein-expressing cells, such as B cell lymphoma, are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 33 OF 133 USPATFULL on STN
AN 2005:229432 USPATFULL <<LOGINID::20080129>>
TI Method of determining interactions with PDZ-domain polypeptides
IN Lu, Peter S., Mountain View, CA, UNITED STATES
Rabinowitz, Joshua D., Mountain View, CA, UNITED STATES
Schweizer, Johannes, Mountain View, CA, UNITED STATES
PA Arbor Vita Corporation, Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 6942981 B1 20050913
AI US 2000-688017 20001013 (9)
RLI Continuation-in-part of Ser. No. US 2000-570118, filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-570364, filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-569525, filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-547276, filed on 11 Apr 2000, ABANDONED
PRAI US 2000-196460P 20000411 (60)
US 2000-196528P 20000411 (60)
US 2000-196527P 20000411 (60)
US 2000-196267P 20000411 (60)
US 2000-182296P 20000214 (60)
US 2000-176195P 20000114 (60)
US 1999-170453P 19991213 (60)
US 1999-162498P 19991029 (60)
US 1999-160860P 19991021 (60)
US 1999-134118P 19990514 (60)
US 1999-134117P 19990514 (60)
US 1999-134114P 19990514 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chan, Christina; Assistant Examiner: Belyavskyi, Michail A
LREP Townsend and Townsend and Crew LLP, Sandbaken, Mark G.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 7901
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for determining interactions between multiple PDZ-domain polypeptides and PDZ Ligand Proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 34 OF 133 USPATFULL on STN
AN 2005:226572 USPATFULL <<LOGINID::20080129>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA
Loss, Troy A E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005196421 A1 20050908
AI US 2004-1417 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 100
ECL Exemplary Claim: 1-7300
DRWN 32 Drawing Page(s)
LN.CNT 34222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 35 OF 133 USPATFULL on STN
AN 2005:220596 USPATFULL <<LOGINID::20080129>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005191331 A1 20050901
AI US 2004-1419 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-2104
DRWN 28 Drawing Page(s)
LN.CNT 56419
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to

inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 36 OF 133 USPATFULL on STN
AN 2005:212065 USPATFULL <<LOGINID::20080129>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005183728 A1 20050825
AI US 2004-7836 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-3411
DRWN 28 Drawing Page(s)
LN.CNT 56413
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L13 ANSWER 37 OF 133 USPATFULL on STN
AN 2005:209494 USPATFULL <<LOGINID::20080129>>

TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181977 A1 20050818
AI US 2004-986231 A1 20041110 (10)
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 182
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 56396
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 38 OF 133 USPATFULL on STN
AN 2005:208533 USPATFULL <<LOGINID::20080129>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181011 A1 20050818
AI US 2004-1792 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 177
ECL Exemplary Claim: 1-4994
DRWN 28 Drawing Page(s)
LN.CNT 56421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 39 OF 133 USPATFULL on STN
AN 2005:208530 USPATFULL <<LOGINID::20080129>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181008 A1 20050818
AI US 2004-1786 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-4736
DRWN 28 Drawing Page(s)
LN.CNT 56377
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an

implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 40 OF 133 USPATFULL on STN
AN 2005:203799 USPATFULL <<LOGINID::20080129>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, CH (non-U.S. corporation)
PI US 2005177225 A1 20050811
AI US 2004-6895 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 173
ECL Exemplary Claim: 1-11788
DRWN 28 Drawing Page(s)
LN.CNT 56371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 41 OF 133 USPATFULL on STN
AN 2005:202245 USPATFULL <<LOGINID::20080129>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175663 A1 20050811
AI US 2004-1791 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 180
ECL Exemplary Claim: 1-3944
DRWN 28 Drawing Page(s)
LN.CNT 56451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 42 OF 133 USPATFULL on STN
AN 2005:190568 USPATFULL <<LOGINID::20080129>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)
PI US 2005165488 A1 20050728
AI US 2004-6912 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 176
ECL Exemplary Claim: 1-3153
DRWN 28 Drawing Page(s)
LN.CNT 56407
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L13 ANSWER 43 OF 133 USPATFULL on STN
AN 2005:189291 USPATFULL <<LOGINID::20080129>>
TI Materials and methods relating to therapy and diagnosis using targeting of cells that express JPL polypeptides
IN Emtage, Peter C. R., Sunnyvale, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Zhao, Qing A., San Jose, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Drmanac, Radoje T., Los Altos Hills, CA, UNITED STATES
PI US 2005164202 A1 20050728
AI US 2003-627373 A1 20030724 (10)
RLI Continuation-in-part of Ser. No. US 2002-293244, filed on 12 Nov 2002, PENDING Continuation-in-part of Ser. No. US 258899, ABANDONED A 371 of International Ser. No. WO 2001-US4098, filed on 5 Feb 2001 Continuation-in-part of Ser. No. US 2000-654936, filed on 1 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-560875, filed on 27 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-496914, filed on 3 Feb 2000, ABANDONED
DT Utility
FS APPLICATION
LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 7462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including types of cancer cells such as melanoma cells, are capable of expressing junctophilin-like (JPL) RNA. Targeting using JPL polypeptides, nucleic acids encoding for JPL polypeptides and anti-JPL antibodies provides a method of killing or inhibiting that growth of melanoma cancer cells that express the JPL protein. Targeting materials and methods for the diagnosis and therapy of melanomas that express JPL are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 44 OF 133 USPATFULL on STN
AN 2005:182941 USPATFULL <<LOGINID::20080129>>
TI Methods of therapy and diagnosis using targeting of cells that express BCLP polypeptides

IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
PI US 2005158324 A1 20050721
AI US 2004-14487 A1 20041215 (11)
RLI Continuation-in-part of Ser. No. US 2003-737666, filed on 15 Dec 2003, PENDING
DT Utility
FS APPLICATION
LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3378
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including cancer cells such as cells from cancers of the colon, breast, lung, ovary, prostate, pancreas and skin are capable of expressing BCLP. Targeting using BCLP polypeptides, nucleic acids encoding for BCLP polypeptides, anti-BCLP antibodies, peptides and small molecules provides a method of killing or inhibiting the growth of the cancer cells that express the BCLP protein. Methods for the diagnosis and therapy of tumors that express BCLP are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 45 OF 133 USPATFULL on STN
AN 2005:172409 USPATFULL <<LOGINID::20080129>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005149158 A1 20050707
AI US 2004-409 A1 20041129 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-274
DRWN 28 Drawing Page(s)
LN.CNT 56404
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis

catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 46 OF 133 USPATFULL on STN
AN 2005:172331 USPATFULL <<LOGINID::20080129>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005149080 A1 20050707
AI US 2004-1418 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-806
DRWN 28 Drawing Page(s)
LN.CNT 56418
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L13 ANSWER 47 OF 133 USPATFULL on STN
AN 2005:171269 USPATFULL <<LOGINID::20080129>>
TI Novel human G-protein coupled receptor, HGPRBMY29sv1 polypeptides
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Hawken, Donald R., Lawrenceville, NJ, UNITED STATES
PI US 2005148016 A1 20050707
AI US 2005-70456 A1 20050302 (11)
RLI Division of Ser. No. US 2002-120604, filed on 11 Apr 2002, PENDING

PRAI US 2001-283145P 20010411 (60)
      US 2001-283161P 20010411 (60)
      US 2001-288468P 20010503 (60)
      US 2001-300619P 20010625 (60)
DT   Utility
FS   APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 10
ECL   Exemplary Claim: 1-20
DRWN 36 Drawing Page(s)
LN.CNT 19887
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 48 OF 133 USPATFULL on STN
AN   2005:165878 USPATFULL <<LOGINID::20080129>>
TI   Intranasal administration of glucose-regulating peptides
IN   Quay, Steven C., Edmonds, WA, UNITED STATES
      Costantino, Henry R., Woodinville, WA, UNITED STATES
PA   Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI   US 2005143303 A1 20050630
AI   US 2004-991597 A1 20041118 (10)
PRAI US 2003-532337P 20031226 (60)
DT   Utility
FS   APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906, US
CLMN Number of Claims: 103
ECL   Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4420
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   Pharmaceutical compositions and methods are described comprising at least one glucose-regulating peptide, such as amylin, glucagon-like peptide-1 (GLP), pramlintide or exendin-4 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the amylin, for treating a variety of diseases and conditions in mammalian subjects, including obesity and diabetes mellitus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 49 OF 133 USPATFULL on STN
AN   2005:151374 USPATFULL <<LOGINID::20080129>>
TI   POLYNUCLEOTIDES ENCODING NOVEL HUMAN PHOSPHATASES
IN   Jackson, Donald G., Lawrenceville, NJ, UNITED STATES

Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Suchard, Suzanne, Wilmington, DE, UNITED STATES
Schieven, Gary, Lawrenceville, NJ, UNITED STATES
Finger, Joshua, San Marcos, CA, UNITED STATES
Todderrud, C. Gordon, Newtown, PA, UNITED STATES
Bassolino, Donna, Hamilton, NJ, UNITED STATES
Krystek, Stanley, Ringoes, NJ, UNITED STATES
Banas, Dana, Hamilton, NJ, UNITED STATES
McAtee, Patrick, Pennigton, NJ, UNITED STATES
PI US 2005130286 A1 20050616
US 7153678 B2 20061226
AI US 2001-29345 A1 20011220 (10)
PRAI US 2000-256868P 20001220 (60)
US 2001-280186P 20010330 (60)
US 2001-287735P 20010501 (60)
US 2001-295848P 20010605 (60)
US 2001-300465P 20010625 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 45
ECL Exemplary Claim: 1-25
DRWN 67 Drawing Page(s)
LN.CNT 23559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 50 OF 133 USPATFULL on STN
AN 2005:150786 USPATFULL <<LOGINID::20080129>>
TI Methods of therapy and diagnosis using targeting of cells that express BCLP polypeptides
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
PI US 2005129697 A1 20050616
AI US 2003-737666 A1 20031215 (10)
DT Utility
FS APPLICATION
LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3289
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Certain cells, including cancer cells such as cells from colon tumors, are capable of expressing BCLP RNA. Targeting using BCLP polypeptides, nucleic acids encoding for BCLP polypeptides, anti-BCLP antibodies, peptides and small molecules provides a method of killing or inhibiting the growth of colon cancer cells that express the BCLP protein. Methods for the diagnosis and therapy of colon tumors that express BCLP are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 51 OF 133 USPATFULL on STN
AN 2005:138619 USPATFULL <<LOGINID::20080129>>
TI Heterocyclic compounds and methods of making and using thereof
IN Rao, Yeleswarapu Koteswar, Hyderabad, INDIA
Pal, Manojit, Hyderabad, INDIA
Sharma, Vedula Manohar, Hyderabad, INDIA
Venkateswarlu, Akella, Hyderabad, INDIA
Pillarisetti, Ram, Norcross, GA, UNITED STATES
PI US 2005119269 A1 20050602
AI US 2004-976284 A1 20041028 (10)
PRAI IN 2003-8612003 20031028
US 2004-610163P 20040915 (60)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O.
BOX 7037, ATLANTA, GA,
30357-0037, US
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I), and methods and/or compositions comprising compounds that are effective in modulating inflammatory responses, such as those resulting from AGE and glycated protein accumulation are provided. Methods and/or compositions comprising compounds that are effective in modulating smooth muscle cell proliferation and the diseases or conditions related thereto are also provided.
##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 52 OF 133 USPATFULL on STN
AN 2005:99051 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
IN Berenson, Ronald J., Mercer Island, WA, UNITED STATES
Bonyhadi, Mark, Issaquah, WA, UNITED STATES
Kalamasz, Dale, Redmond, WA, UNITED STATES
PA XCYTE Therapies, Inc., Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2005084967 A1 20050421
AI US 2004-900046 A1 20040727 (10)
RLI Continuation-in-part of Ser. No. US 2003-729822, filed on 5 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-603577, filed on 24 Jun 2003, ABANDONED
PRAI US 2003-442001P 20030122 (60)
US 2002-431212P 20021204 (60)
US 2002-393042P 20020628 (60)
DT Utility
FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 3575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g. autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 53 OF 133 USPATFULL on STN
AN 2005:56705 USPATFULL <<LOGINID::20080129>>
TI Polynucleotides encoding a novel human neuronal cell adhesion protein, BGS-28, and variants thereof
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
PI US 2005048620 A1 20050303
AI US 2004-926386 A1 20040825 (10)
PRAI US 2003-498170P 20030827 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 13839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding BGS-28 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-28 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 54 OF 133 USPATFULL on STN
AN 2005:44237 USPATFULL <<LOGINID::20080129>>
TI Molecular interactions in hematopoietic cells
IN Lu, Peter S., Mountain View, CA, UNITED STATES
Rabinowitz, Joshua D., Mountain View, CA, UNITED STATES
Schweizer, Johannes, Mountain View, CA, UNITED STATES
PA Arbor Vita Corporation, Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 2005037969 A1 20050217
AI US 2004-938249 A1 20040910 (10)
RLI Continuation of Ser. No. US 2000-724553, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2000-710059, filed on 10 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-688017, filed on 13 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-570118, filed

on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-570364, filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-569525, filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-547276, filed on 11 Apr 2000, ABANDONED

PRAI US 2000-196460P 20000411 (60)
US 2000-196528P 20000411 (60)
US 2000-196527P 20000411 (60)
US 2000-196267P 20000411 (60)
US 2000-182296P 20000214 (60)
US 2000-176195P 20000114 (60)
US 1999-170453P 19991213 (60)
US 1999-162498P 19991029 (60)
US 1999-160860P 19991021 (60)
US 1999-134118P 19990514 (60)
US 1999-134117P 19990514 (60)
US 1999-134114P 19990514 (60)

DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 10548
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 55 OF 133 USPATFULL on STN
AN 2005:36876 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for enhanced mucosal delivery of growth hormone
IN Quay, Steven C., Edmonds, WA, UNITED STATES
de Meireles, Jorge C., Syosset, NY, UNITED STATES
Gupta, Malini, Dix Hills, NY, UNITED STATES
Vangala, Shyam, Dayton, OH, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2005031549 A1 20050210
AI US 2004-862141 A1 20040601 (10)
PRAI US 2003-477403P 20030609 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906
CLMN Number of Claims: 70
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4971
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical formulations are described comprising at least one growth hormone and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the growth hormone. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of growth hormone to the blood plasma, for example, by yielding a peak concentration (C.sub.max) of the growth hormone in an hepatic portal vein or a blood plasma of the subject that is 20% or greater

compared to a peak concentration of the growth hormone in the hepatic portal vein or the blood plasma of the subject following administration to the subject of a same concentration or dose of the growth hormone to the subject by subcutaneous injection. Exemplary formulations and methods within the invention utilize human growth hormone as the hormone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 56 OF 133 USPATFULL on STN
AN 2005:3825 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
IN Quay, Steven C., Edmonds, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)
PI US 2005002927 A1 20050106
US 7186692 B2 20070306
AI US 2004-869649 A1 20040616 (10)
RLI Continuation-in-part of Ser. No. US 2003-745069, filed on 23 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING
PRAI US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY, INC., 3450 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-8906
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 6187
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 57 OF 133 USPATFULL on STN
AN 2004:334808 USPATFULL <<LOGINID::20080129>>
TI Novel human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
PI US 2004265890 A1 20041230
US 7183379 B2 20070227
AI US 2004-882761 A1 20040701 (10)
RLI Division of Ser. No. US 2001-29347, filed on 20 Dec 2001, PENDING
PRAI US 2000-257774P 20001222 (60)
DT Utility
FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 14389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 58 OF 133 USPATFULL on STN
AN 2004:326844 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for enhanced mucosal delivery of interferon alpha
IN Quay, Steven C., Edmonds, WA, UNITED STATES
El-Shafy, Mohammed Abd, Hauppauge, NY, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004258663 A1 20041223
AI US 2004-840536 A1 20040506 (10)
PRAI US 2003-469079P 20030508 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4753
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods are provided for intranasal delivery of interferon-α yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon-α is delivered to the intranasal mucosa along with one or more intranasal delivery-enhancing agent(s) to yield substantially increased absorption and/or bioavailability of the interferon-α and/or a substantially decreased time to maximal concentration of interferon-α in a tissue of a subject as compared to controls where the interferon-α is administered to the same intranasal site alone or formulated according to previously disclosed reports. The enhancement of intranasal delivery of interferon-α according to the methods and compositions of the present invention allows for the effective pharmaceutical use of these agents to treat a variety of diseases and conditions in mammalian subjects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 59 OF 133 USPATFULL on STN
AN 2004:274270 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity

IN Quay, Steven C., Edmonds, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
Kleppe, Mary S., Kingston, WA, UNITED STATES
MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004214772 A1 20041028
US 7229966 B2 20070612
AI US 2004-780325 A1 20040217 (10)
RLI Continuation of Ser. No. US 2003-745069, filed on 23 Dec 2003, PENDING
Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING
PRAI WO 2003-US40538 20031217
US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 6250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 60 OF 133 USPATFULL on STN
AN 2004:268264 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
IN Quay, Steven C., Edmonds, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
Kleppe, Mary S., Kingston, WA, UNITED STATES
MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004209807 A1 20041021
US 7157426 B2 20070102
AI US 2004-768288 A1 20040130 (10)
RLI Continuation of Ser. No. US 2003-745069, filed on 23 Dec 2003, PENDING
Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING
PRAI WO 2003-US40538 20031217
US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP Paul G. Lunn, Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906

CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 6161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 61 OF 133 USPATFULL on STN
AN 2004:262074 USPATFULL <<LOGINID::20080129>>
TI Polynucleotides encoding a novel human phosphatase, BMY_HPP13
IN Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Schieven, Gary L., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
PI US 2004204576 A1 20041014
AI US 2003-612742 A1 20030702 (10)
PRAI US 2002-393253P 20020702 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 15403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding a human phosphatase polypeptide, BMY_HPP13, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptide. The invention further relates to diagnostic and therapeutic methods for applying this novel human phosphatase polypeptide to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 62 OF 133 USPATFULL on STN
AN 2004:226988 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
IN Berenson, Ronald, Mercer Island, WA, UNITED STATES
Bonyhadi, Mark, Issaquah, WA, UNITED STATES
Kalamasz, Dale, Redmond, WA, UNITED STATES
PA XCYTE Therapies, Inc., Seattle, WA (U.S. corporation)
PI US 2004175373 A1 20040909
AI US 2003-729822 A1 20031205 (10)
RLI Continuation-in-part of Ser. No. US 2003-603577, filed on 24 Jun 2003, PENDING

PRAI US 2003-442001P 20030122 (60)
US 2002-431212P 20021204 (60)
US 2002-393042P 20020628 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 3482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g. autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 63 OF 133 USPATFULL on STN
AN 2004:203885 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
IN Quay, Steven C., Edmonds, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
Kleppe, Mary S., Kingston, WA, UNITED STATES
MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004157777 A1 20040812
US 7186691 B2 20070306
AI US 2003-745069 A1 20031223 (10)
RLI Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING
PRAI US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031008 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY, INC., 3450 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-8906
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 6226
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 64 OF 133 USPATFULL on STN

AN 2004:196400 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
IN Berenson, Ronald, Mercer Island, WA, UNITED STATES
Bonyhadi, Mark, Issaquah, WA, UNITED STATES
Kalamasz, Dale, Redmond, WA, UNITED STATES
PA XCYTE Therapies, Inc., Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2004151704 A1 20040805
AI US 2003-603577 A1 20030624 (10)
PRAI US 2003-442001P 20030122 (60)
US 2002-431212P 20021204 (60)
US 2002-393042P 20020628 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g. autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 65 OF 133 USPATFULL on STN
AN 2004:150914 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PI US 2004115135 A1 20040617
US 7166575 B2 20070123
AI US 2002-322266 A1 20021217 (10)
DT Utility
FS APPLICATION
LREP WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 94
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 9307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of peptide YY to the blood plasma or central nervous system (CNS) tissue or fluid, for example, by yielding a peak concentration (C.sub.max) of the peptide YY in the blood plasma or CNS tissue or fluid of the subject that is 20% or greater compared to a peak concentration of the peptide YY in the blood plasma or CNS tissue or fluid of the subject following administration to the subject of a same

concentration or dose of the peptide YY to the subject by subcutaneous injection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 66 OF 133 USPATFULL on STN
AN 2004:101671 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004077540 A1 20040422
AI US 2003-601953 A1 20030624 (10)
PRAI US 2002-392512P 20020628 (60)
DT Utility
FS APPLICATION
LREP PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY, INC., 3450 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-8906
CLMN Number of Claims: 92
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 13170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject. This effect typically involves inhibition by the permeabilizing agent of homotypic or heterotypic binding between epithelial membrane adhesive proteins of neighboring epithelial cells. Target proteins for this blockade of homotypic or heterotypic binding can be selected from various related junctional adhesion molecules (JAMs), occludins, or claudins. The permeabilizing agent is typically a peptide or peptide analog or mimetic, often selected or derived from an extracellular domain of a mammalian JAM, occludin or claudin protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 67 OF 133 USPATFULL on STN
AN 2004:77102 USPATFULL <<LOGINID::20080129>>
TI Ii-key/antigenic epitope hybrid peptide vaccines
IN Humphreys, Robert E., Acton, MA, UNITED STATES
Xu, Minzhen, Northborough, MA, UNITED STATES
PA Antigen Express, Inc., Worcester, MA (U.S. corporation)
PI US 2004058881 A1 20040325
US 7179645 B2 20070220
AI US 2002-253286 A1 20020924 (10)
DT Utility
FS APPLICATION
LREP Kevin M. Farrell, Pierce Atwood, Suite 350, One New Hampshire Avenue, Portsmouth, NH, 03801
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7924
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a nucleic acid molecule comprising a first expressible

sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 68 OF 133 USPATFULL on STN
AN 2004:63784 USPATFULL <<LOGINID::20080129>>
TI Novel metalloprotease polypeptide, MP-1
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2004048302 A1 20040311
AI US 2003-651722 A1 20030829 (10)
RLI Division of Ser. No. US 2002-67443, filed on 5 Feb 2002, GRANTED, Pat. No. US 6642041
PRAI US 2001-266518P 20010205 (60)
US 2001-282814P 20010410 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 43 Drawing Page(s)
LN.CNT 15444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding MP-1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 69 OF 133 USPATFULL on STN
AN 2004:57405 USPATFULL <<LOGINID::20080129>>
TI Polynucleotides encoding a novel metalloprotease, MP-1
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2004043407 A1 20040304
AI US 2003-649273 A1 20030827 (10)
RLI Continuation of Ser. No. US 2002-67443, filed on 5 Feb 2002, GRANTED, Pat. No. US 6642041
PRAI US 2001-266518P 20010205 (60)
US 2001-282814P 20010410 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 15462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding MP-1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 70 OF 133 USPATFULL on STN
AN 2004:50383 USPATFULL <<LOGINID::20080129>>
TI Compositions and methods for enhanced mucosal delivery of interferon beta
IN Quay, Steven C., Edmonds, WA, UNITED STATES
Gupta, Malini, Dix Hills, NY, UNITED STATES
de Meireles, Jorge C., Syosset, NY, UNITED STATES
Abd El-Shafy, Mohammed, Hauppauge, NY, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004037809 A1 20040226
AI US 2003-462452 A1 20030616 (10)
PRAI US 2002-393066P 20020628 (60)
DT Utility
FS APPLICATION
LREP PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY, INC., 3450 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-8906
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods are provided for intranasal delivery of interferon-β yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon-β is delivered to the intranasal mucosa along with one or more intranasal delivery-enhancing agent(s) to yield substantially increased absorption and/or bioavailability of the interferon-β and/or a substantially decreased time to maximal concentration of interferon-β in a tissue of a subject as compared to controls where the interferon-β is administered to the same intranasal site alone or formulated according to previously disclosed

reports. The enhancement of intranasal delivery of interferon-β according to the methods and compositions of the present invention allows for the effective pharmaceutical use of these agents to treat a variety of diseases and conditions in mammalian subjects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 71 OF 133 USPATFULL on STN
AN 2004:44514 USPATFULL <<LOGINID::20080129>>
TI Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
IN Farrelly, Dennis, Monmouth Junction, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Wu, Shujian, Langhorne, PA, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
PI US 2004033506 A1 20040219
AI US 2002-308128 A1 20021202 (10)
PRAI US 2001-334904P 20011130 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 37 Drawing Page(s)
LN.CNT 28557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding Mitochondrial GPAT, Microsomal GPAT_hlog1, Microsomal GPAT_hlog2, Microsomal GPAT_hlog3, and/or Microsomal GPAT_hlog3_v1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel Mitochondrial GPAT, Microsomal GPAT_hlog1, Microsomal GPAT_hlog2, Microsomal GPAT_hlog3, and/or Microsomal GPAT_hlog3_v1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 72 OF 133 USPATFULL on STN
AN 2004:38077 USPATFULL <<LOGINID::20080129>>
TI Dopamine agonist formulations for enhanced central nervous system delivery
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)
PI US 2004028613 A1 20040212
AI US 2001-891630 A1 20010625 (9)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 58
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)

LN.CNT 8045
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical formulations are described comprising at least one dopamine receptor agonist and one or more mucosal delivery-enhancing agents for enhanced mucosal delivery of the dopamine receptor agonist. In one aspect, the mucosal delivery formulations and methods provide enhanced delivery of the dopamine receptor agonist to the central nervous sytstem (CNS), for example by yielding dopamine receptor agonist concentrations in the cerebral spinal fluid of 5% or greater of the peak dopamine agonist concentrations in the blood plasma following administration to a mammalian subject. Exemplary formulations and methods within the invention utilize apomorphine as the dopamine receptor agonist. Other exemplary methods and formulations focus in intranasal administration of a dopamine receptor agonist. The formulations and methods of the invention are useful for treating a variety of diseases and conditions in mammalian subjects, including Parkinson's disease, male erectile dysfunction, female sexual dysfunction, among others. In alternate aspects, the mucosal delivery formulations and methods of the invention include one, or any combination of, mucosal delivery-enhancing agents selected from (a) aggregation inhibitory agents; (b) charge modifying agents; (c) pH control agents; (d) degradative enzyme inhibitors; (e) mucolytic or mucus clearing agents; (f) ciliostatic agents; (g) membrane penetration-enhancing agents; (h) modulatory agents of epithelial junction physiology; (i) vasodilator agents; (j) selective transport-enhancing agents; and (k) stabilizing delivery vehicles, carriers, supports or complex-forming agents. These methods and formulations of the invention provide for significantly enhanced absorption of dopamine receptor agonists into or across a nasal mucosal barrier to a target site of action, for example the CNS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 73 OF 133 USPATFULL on STN
AN 2004:7465 USPATFULL <<LOGINID::20080129>>
TI Poroplasts
IN Surber, Mark W., Coronado, CA, UNITED STATES
Giacalone, Matthew, San Diego, CA, UNITED STATES
PI US 2004005700 A1 20040108
AI US 2002-157339 A1 20020528 (10)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 74 OF 133 USPATFULL on STN
AN 2004:7358 USPATFULL <<LOGINID::20080129>>
TI Materials and methods relating to therapy and diagnosis using targeting of cells that express DCAL-Hy polypeptides

IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
Goodrich, Ryle W., Los Angeles, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
PI US 2004005592 A1 20040108
AI US 2003-379127 A1 20030303 (10)
RLI Continuation-in-part of Ser. No. US 2001-799451, filed on 5 Mar 2001, PENDING
DT Utility
FS APPLICATION
LREP NUVELO, 675 ALMANOR AVE., SUNNYVALE, CA, 94085
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 7657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel human DCAL-Hy polypeptides. Other aspects of the invention include vectors containing processes for producing novel human DCAL-Hy polypeptides, and antibodies specific for such polypeptides. Targeting DCAL-Hy using DCAL-Hy polypeptides, nucleic acids encoding for DCAL-Hy polypeptides, anti-DCAL-Hy antibodies, and other binding peptides and small molecules provides a method of killing or inhibiting that growth of cancer cells that express the DCAL-Hy protein. Methods of therapy and diagnosis of disorders associated with DCAL-Hy protein-expressing cells, such as DCAL-Hy, are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 75 OF 133 USPATFULL on STN
AN 2003:334718 USPATFULL <<LOGINID::20080129>>
TI Ii-Key/antigenic epitope hybrid peptide vaccines
IN Humphreys, Robert, Acton, MA, UNITED STATES
Xu, Minzhen, Northborough, MA, UNITED STATES
PA Antigen Express, Inc., Worcester, MA, UNITED STATES, 01606 (U.S. corporation)
PI US 2003235594 A1 20031225
AI US 2002-245871 A1 20020917 (10)
RLI Continuation-in-part of Ser. No. US 2002-197000, filed on 17 Jul 2002, PENDING Division of Ser. No. US 1999-396813, filed on 14 Sep 1999, GRANTED, Pat. No. US 6432409
DT Utility
FS APPLICATION
LREP Kevin M. Farrell, Kevin M. Farrell, P.C., P.O. Box 999, York Harbor, ME, 03911
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7893
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is an antigen presentation enhancing hybrid polypeptide which includes three elements. The first element is an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity. The second element is a chemical structure covalently linking the N-terminal element described above to the MHC Class II-presented epitope described below. The chemical structure is a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged

in a linear fashion, the chemical structure being selected from the group consisting of: i) immunologically neutral chemical structures, ii) a MHC Class I epitope or a portion thereof, and/or iii) an antibody-recognized determinant or a portion thereof. Finally, the enhancing antigen presentation enhancing hybrid polypeptide includes a C-terminal element comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 76 OF 133 USPATFULL on STN
AN 2003:330124 USPATFULL <<LOGINID::20080129>>
TI Minicell-based screening for compounds and proteins that modulate the activity of signalling proteins
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003232335 A1 20031218
AI US 2002-157317 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 77 OF 133 USPATFULL on STN
AN 2003:318700 USPATFULL <<LOGINID::20080129>>
TI Antibodies to native conformations of membrane proteins
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003224444 A1 20031204
AI US 2002-157491 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 78 OF 133 USPATFULL on STN
AN 2003:318625 USPATFULL <<LOGINID::20080129>>
TI Reverse screening and target identification with minicells
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Gerhart, William, La Mesa, CA, UNITED STATES
PI US 2003224369 A1 20031204
AI US 2002-157171 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18610
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 79 OF 133 USPATFULL on STN
AN 2003:312291 USPATFULL <<LOGINID::20080129>>
TI Minicell-based bioremediation
IN Segall, Anca M., San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003219888 A1 20031127
AI US 2002-157418 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18632
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 80 OF 133 USPATFULL on STN
AN 2003:311814 USPATFULL <<LOGINID::20080129>>
TI Methods of making pharmaceutical compositions with minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003219408 A1 20031127

AI US 2002-157320 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18632
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 81 OF 133 USPATFULL on STN
AN 2003:300375 USPATFULL <<LOGINID::20080129>>
TI Minicell-based delivery agents
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003211599 A1 20031113
AI US 2002-157106 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18671
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 82 OF 133 USPATFULL on STN
AN 2003:299865 USPATFULL <<LOGINID::20080129>>
TI Minicell-based selective absorption
IN Berkley, Neil, San Diego, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003211086 A1 20031113
AI US 2002-157073 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET, FOURTEENTH FLOOR,

IRVINE, CA, 92614
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 83 OF 133 USPATFULL on STN
AN 2003:294815 USPATFULL <<LOGINID::20080129>>
TI Pharmaceutical compositions with minicells
IN Berkley, Neil, San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003207833 A1 20031106
AI US 2002-156811 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18585
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 84 OF 133 USPATFULL on STN
AN 2003:289309 USPATFULL <<LOGINID::20080129>>
TI Polynucleotide encoding a novel methionine aminopeptidase, protease-39
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Naglich, Joseph, Yardley, PA, UNITED STATES
PI US 2003204070 A1 20031030
AI US 2003-350516 A1 20030123 (10)
PRAI US 2002-351251P 20020123 (60)
US 2002-362872P 20020308 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 17388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding Protease-39 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel Protease-39 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 85 OF 133 USPATFULL on STN
AN 2003:288723 USPATFULL <<LOGINID::20080129>>
TI Conjugated minicells
IN Surber, Mark W., Coronado, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003203481 A1 20031030
AI US 2002-157213 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 86 OF 133 USPATFULL on STN
AN 2003:288653 USPATFULL <<LOGINID::20080129>>
TI Methods of minicell-based delivery
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003203411 A1 20031030
AI US 2002-156792 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18582
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as

diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 87 OF 133 USPATFULL on STN
AN 2003:288179 USPATFULL <<LOGINID::20080129>>
TI Minicell-based diagnostics
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003202937 A1 20031030
AI US 2002-157178 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18527
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 88 OF 133 USPATFULL on STN
AN 2003:282746 USPATFULL <<LOGINID::20080129>>
TI Membrane to membrane delivery
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003199089 A1 20031023
AI US 2002-157318 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18530
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 89 OF 133 USPATFULL on STN
AN 2003:282745 USPATFULL <<LOGINID::20080129>>
TI Minicell-based gene therapy

IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
    Berkley, Neil, San Diego, CA, UNITED STATES
    Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003199088 A1 20031023
    US 7183105 B2 20070227
AI US 2002-156902 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
    US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET, FOURTEENTH FLOOR,
    IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 15300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 90 OF 133 USPATFULL on STN
AN 2003:282662 USPATFULL <<LOGINID::20080129>>
TI Solid supports with minicells
IN Sabbadini, Roger, Lakeside, CA, UNITED STATES
    Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003199005 A1 20031023
AI US 2002-157166 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
    US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET, FOURTEENTH FLOOR,
    IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 91 OF 133 USPATFULL on STN
AN 2003:282653 USPATFULL <<LOGINID::20080129>>
TI Minicell libraries
IN Surber, Mark W., Coronado, CA, UNITED STATES
    Berkley, Neil, San Diego, CA, UNITED STATES
    Gerhart, William, La Mesa, CA, UNITED STATES
    Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003198996 A1 20031023
AI US 2002-157147 A1 20020528 (10)

RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2001-293566P 20010524 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 92 OF 133 USPATFULL on STN
AN 2003:282652 USPATFULL <<LOGINID::20080129>>
TI Forward screening with minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
Gerhart, William, La Mesa, CA, UNITED STATES
PI US 2003198995 A1 20031023
AI US 2002-156831 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 93 OF 133 USPATFULL on STN
AN 2003:277136 USPATFULL <<LOGINID::20080129>>
TI Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Cheng, Janet D., Lawrenceville, NJ, UNITED STATES
PI US 2003195163 A1 20031016
US 7223558 B2 20070529

AI US 2002-193477 A1 20020711 (10)
PRAI US 2001-304888P 20010711 (60)
US 2002-372147P 20020412 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 19137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding BGS-2, 3, and 4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-2, 3, and 4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 94 OF 133 USPATFULL on STN
AN 2003:276773 USPATFULL <<LOGINID::20080129>>
TI Minicell compositions and methods
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003194798 A1 20031016
AI US 2002-154951 A1 20020524 (10)
PRAI US 2001-293566P 20010524 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18583
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 95 OF 133 USPATFULL on STN
AN 2003:276689 USPATFULL <<LOGINID::20080129>>
TI Minicell-based transformation
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003194714 A1 20031016
AI US 2002-157299 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)

DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18595
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 96 OF 133 USPATFULL on STN
AN 2003:271146 USPATFULL <<LOGINID::20080129>>
TI Minicell-producing parent cells
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Segall, Anca M., San Diego, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003190749 A1 20031009
AI US 2002-157215 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18577
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 97 OF 133 USPATFULL on STN
AN 2003:271080 USPATFULL <<LOGINID::20080129>>
TI Minicell-based rational drug design
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003190683 A1 20031009
AI US 2002-157302 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614

CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 98 OF 133 USPATFULL on STN
AN 2003:270998 USPATFULL <<LOGINID::20080129>>
TI Target display on minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronada, CA, UNITED STATES
PI US 2003190601 A1 20031009
AI US 2002-157096 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18581
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 99 OF 133 USPATFULL on STN
AN 2003:238122 USPATFULL <<LOGINID::20080129>>
TI Minicell-based transfection
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003166279 A1 20030904
AI US 2002-157391 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18548
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as

diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

L13 ANSWER 100 OF 133 USPATFULL on STN
AN 2003:237942 USPATFULL <<LOGINID::20080129>>
TI Minicells comprising membrane proteins
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Segall, Anca M., San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003166099 A1 20030904
AI US 2002-157305 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18580
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 101 OF 133 USPATFULL on STN
AN 2003:225786 USPATFULL <<LOGINID::20080129>>
TI Novel human G-protein coupled receptor, HGPRBMY23, expressed highly in kidney
IN Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Cacace, Angela, Clinton, CT, UNITED STATES
Barber, Lauren, Griswold, CT, UNITED STATES
Ryseck, Rolf P., Ewing, NJ, UNITED STATES
PI US 2003157598 A1 20030821
AI US 2001-10568 A1 20011207 (10)
PRAI US 2000-251926P 20001207 (60)
US 2001-269795P 20010214 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 15361
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HGPRBMY23 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY23

polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly renal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 102 OF 133 USPATFULL on STN
AN 2003:219773 USPATFULL <<LOGINID::20080129>>
TI Novel human G-protein coupled receptor, HGPRBMY11, expressed highly in heart and variants thereof
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Cacace, Angela M., Clinton, CT, UNITED STATES
Barber, Lauren E., Griswood, CT, UNITED STATES
PI US 2003153063 A1 20030814
AI US 2001-991225 A1 20011116 (9)
PRAI US 2000-249613P 20001117 (60)
US 2000-257611P 20001221 (60)
US 2001-305818P 20010716 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 16070
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HGPRBMY11 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of the HGPRBMY11 polypeptide, HGPRBMY11v1 and HGPRBMY11v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY11, HGPRBMY11v1, and/or HGPRBMY11v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 103 OF 133 USPATFULL on STN
AN 2003:207348 USPATFULL <<LOGINID::20080129>>
TI Novel human leucine-rich repeat containing protein expressed predominately in bone marrow, HLRRBM1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
PI US 2003143706 A1 20030731
AI US 2001-28374 A1 20011220 (10)
PRAI US 2000-257773P 20001222 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 13850
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly immune diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 104 OF 133 USPATFULL on STN
AN 2003:200810 USPATFULL <<LOGINID::20080129>>
TI Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, BGS-8, expressed highly in immune tissue
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Lee, Liana M., North Brunswick, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
PI US 2003138795 A1 20030724
AI US 2002-173461 A1 20020614 (10)
PRAI US 2001-298340P 20010614 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 13042
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding BGS-8 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-8 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 105 OF 133 USPATFULL on STN
AN 2003:166515 USPATFULL <<LOGINID::20080129>>
TI Polynucleotide encoding a novel cysteine protease of the calpain superfamily, CAN-12, and variants thereof
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES
Vaz, Roy J., North Branch, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES

PI US 2003114373 A1 20030619
    US 7186564 B2 20070306
AI US 2002-116519 A1 20020403 (10)
PRAI US 2001-281253P 20010403 (60)
    US 2001-288768P 20010504 (60)
    US 2001-296180P 20010606 (60)
    US 2001-300620P 20010625 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 30149
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding CAN-12 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of CAN-12 polypeptides, CAN-12v1 and CAN-12v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel CAN-12, CAN-12v1, and CAN-12v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly neuro- and musculo-degenerative conditions. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 106 OF 133 USPATFULL on STN
AN 2003:165871 USPATFULL <<LOGINID::20080129>>
TI Human single nucleotide polymorphisms
IN Tsuchihashi, Zenta, Pennington, NJ, UNITED STATES
    Hui, Lester, Fairfax, VA, UNITED STATES
    Zerba, Kim, New Hope, PA, UNITED STATES
    Ma-Edmonds, Manling, Lawrenceville, NJ, UNITED STATES
    Perrone, Mark, Princeton, NJ, UNITED STATES
    Swanson, Brian, Yardley, PA, UNITED STATES
    Powell, James, Lumberville, PA, UNITED STATES
PI US 2003113726 A1 20030619
AI US 2001-5956 A1 20011203 (10)
PRAI US 2000-251015P 20001204 (60)
    US 2001-263678P 20010123 (60)
    US 2001-273037P 20010302 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 108 Drawing Page(s)
LN.CNT 21863
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides polynucleotides and polypeptides corresponding to novel gene sequences associated with the incidence of cardiovascular disorders. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these genes which comprise at least one polymorphic site per fragment. Allele-specific

primers and probes which hybridize to these regions, and/or which comprise at least one polymorphic site are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, paternity testing, medicine, and genetic analysis. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders, particularly cardiovascular diseases related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 107 OF 133 USPATFULL on STN
AN 2003:140506 USPATFULL <<LOGINID::20080129>>
TI Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Hawken, Donald R., Lawrenceville, NJ, UNITED STATES
PI US 2003096347 A1 20030522
US 7049096 B2 20060523
AI US 2002-120604 A1 20020411 (10)
PRAI US 2001-283145P 20010411 (60)
US 2001-283161P 20010411 (60)
US 2001-288468P 20010503 (60)
US 2001-300619P 20010625 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 36 Drawing Page(s)
LN.CNT 20308
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 108 OF 133 USPATFULL on STN
AN 2003:127127 USPATFULL <<LOGINID::20080129>>
TI Novel human leucine-rich repeat containing protein expressed

predominately in nervous system tissues, HLRRNS1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
PI US 2003087340 A1 20030508
AI US 2001-28392 A1 20011220 (10)
PRAI US 2001-259479P 20010103 (60)
US 2001-260616P 20010109 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 15374
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRNS1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRNS1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly nervous system diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 109 OF 133 USPATFULL on STN
AN 2003:120301 USPATFULL <<LOGINID::20080129>>
TI Polynucleotides encoding a novel metalloprotease, MP-1
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2003082782 A1 20030501
US 6642041 B2 20031104
AI US 2002-67443 A1 20020205 (10)
PRAI US 2001-266518P 20010205 (60)
US 2001-282814P 20010410 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 17186
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding MP-1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present

invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 110 OF 133 USPATFULL on STN
AN 2003:86317 USPATFULL <<LOGINID::20080129>>
TI Polynucleotide encoding a novel human potassium channel alpha-subunit, K+alphaM1, and variants thereof
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana M., North Brunswick, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra, Wallingford, CT, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
PI US 2003059923 A1 20030327
AI US 2001-999220 A1 20011101 (9)
PRAI US 2000-245383P 20001102 (60)
US 2000-257780P 20001221 (60)
US 2001-269854P 20010220 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 30 Drawing Page(s)
LN.CNT 16037
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding K+alphaM1 polypeptides, fragments and homologues thereof. The invention also provides novel polynucleotides encoding the K+alphaM1 variant polypeptides, K+alphaM1.v1 and K+alphaM1.v2, in addition to fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+alphaM1, K+alphaM1.v1, and K+alphaM1.v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 111 OF 133 USPATFULL on STN
AN 2003:78525 USPATFULL <<LOGINID::20080129>>
TI Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas, Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Cheney, Daniel L., Flemington, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2003054445 A1 20030320
US 7247717 B2 20070724
AI US 2001-993180 A1 20011114 (9)
PRAI US 2000-248434P 20001114 (60)
US 2000-257610P 20001221 (60)

US 2001-282745P 20010410 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 14427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 112 OF 133 USPATFULL on STN
AN 2003:45474 USPATFULL <<LOGINID::20080129>>
TI Polynucleotide encoding a novel human potassium channel beta-subunit, K+betaM2
IN Chang, Han, Princeton Junction, NY, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John, Belle Mead, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Carroll, Pamela, Princeton, NJ, UNITED STATES
PI US 2003032786 A1 20030213
AI US 2002-56884 A1 20020124 (10)
PRAI US 2001-263872P 20010124 (60)
US 2001-269794P 20010214 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 13633
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding K+betaM2 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+betaM2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 113 OF 133 USPATFULL on STN
AN   2003:45464 USPATFULL <<LOGINID::20080129>>
TI   Polynucleotide encoding a novel human potassium channel beta-subunit, K+Mbeta1
IN   Feder, John N., Belle Mead, NJ, UNITED STATES
       Lee, Liana, North Brunswick, NJ, UNITED STATES
       Chen, Jian, Princeton, NJ, UNITED STATES
       Jackson, Donald, Lawrenceville, NJ, UNITED STATES
       Ramanathan, Chandra, Wallingford, CT, UNITED STATES
       Siemers, Nathan, Pennington, NJ, UNITED STATES
       Chang, Han, Princeton Junction, NJ, UNITED STATES
PI   US 2003032776   A1 20030213
AI   US 2001-40805   A1 20011101 (10)
PRAI   US 2000-245366P   20001102 (60)
       US 2000-257851P   20001221 (60)
DT   Utility
FS   APPLICATION
LREP   STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN   Number of Claims: 35
ECL   Exemplary Claim: 1
DRWN   6 Drawing Page(s)
LN.CNT 12037
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   The present invention provides novel polynucleotides encoding K+Mbeta1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+Mbeta1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 114 OF 133 USPATFULL on STN
AN   2003:37516 USPATFULL <<LOGINID::20080129>>
TI   Human cDNAs and proteins and uses thereof
IN   Bejanin, Stephane, Paris, FRANCE
       Tanaka, Hiroaki, Antony, FRANCE
PA   GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI   US 2003027161   A1 20030206
       US 7074571   B2 20060711
AI   US 2001-992600   A1 20011113 (9)
RLI   Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI   WO 2001-IB1715   20010806
       US 2001-305456P   20010713 (60)
       US 2001-302277P   20010629 (60)
       US 2001-298698P   20010615 (60)
       US 2001-293574P   20010525 (60)
DT   Utility
FS   APPLICATION
LREP   John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN   Number of Claims: 13
ECL   Exemplary Claim: 1
DRWN   4 Drawing Page(s)
LN.CNT 25529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 115 OF 133 USPATFULL on STN
AN 2003:23722 USPATFULL <<LOGINID::20080129>>
TI Novel human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
PI US 2003017562 A1 20030123
US 6858407 B2 20050222
AI US 2001-29347 A1 20011220 (10)
PRAI US 2000-257774P 20001222 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 14217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 116 OF 133 USPAT2 on STN
AN 2007:224799 USPAT2 <<LOGINID::20080129>>
TI Polynucleotides encoding a novel human G-protein coupled receptor splice variant, HGPRBMY29SV2
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7276354 B2 20071002
AI US 2005-71761 20050303 (11)
RLI Division of Ser. No. US 2002-120604, filed on 11 Apr 2002, Pat. No. US 7049096
PRAI US 2001-283145P 20010411 (60)
US 2001-283161P 20010411 (60)
US 2001-288468P 20010503 (60)
US 2001-300619P 20010625 (60)

DT Utility
FS GRANTED
EXNAM Primary Examiner: Landsman, Robert S.
LREP D'Amico, Stephen C.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 36 Drawing Figure(s); 36 Drawing Page(s)
LN.CNT 20073
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing these polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing these polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 117 OF 133 USPAT2 on STN
AN 2006:174525 USPAT2 <<LOGINID::20080129>>
TI Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
IN Chen, Jian, Princeton, NJ, UNITED STATES
Nelson, Thomas, Lawrenceville, NJ, UNITED STATES
Bassolino, Donna A, Hamilton, NJ, UNITED STATES
Cheney, Daniel L., Flemington, NJ, UNITED STATES
PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7256267 B2 20070814
AI US 2006-329900 20060111 (11)
RLI Division of Ser. No. US 2001-993180, filed on 14 Nov 2001, PENDING
PRAI US 2001-282745P 20010410 (60)
US 2000-257610P 20001221 (60)
US 2000-248434P 20001114 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Nashed, Nashaat T.; Assistant Examiner: Moore, William W.
LREP D'Amico, Stephen C.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 18789
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present

invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 118 OF 133 USPAT2 on STN
AN 2005:151374 USPAT2 <<LOGINID::20080129>>
TI Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof
IN Jackson, Donald G., Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, San Francisco, CA, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Suchard, Suzanne J., Wilmington, DE, UNITED STATES
Finger, Joshua, Spring City, PA, UNITED STATES
Todderud, C. Gordon, Newtown, PA, UNITED STATES
Banas, Dana, Hamilton, NJ, UNITED STATES
PA Bristol-Myers Squibb, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7153678 B2 20061226
AI US 2001-29345 20011220 (10)
PRAI US 2001-300465P 20010625 (60)
US 2001-295848P 20010605 (60)
US 2001-287735P 20010501 (60)
US 2001-280186P 20010330 (60)
US 2000-256868P 20001220 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Prouty, Rebecca E.
LREP D'Amico, Stephen C.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 67 Drawing Figure(s); 67 Drawing Page(s)
LN.CNT 23952
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 119 OF 133 USPAT2 on STN
AN 2005:3825 USPAT2 <<LOGINID::20080129>>
TI Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
IN Quay, Steven C., Edmonds, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)
PI US 7186692 B2 20070306
AI US 2004-869649 20040616 (10)
RLI Continuation-in-part of Ser. No. US 2003-745069, filed on 23 Dec 2003,

PENDING Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING
PRAI US 2003-518812P 20031110 (60)
US 2003-517290P 20031104 (60)
US 2003-510785P 20031010 (60)
US 2003-501170P 20030908 (60)
US 2003-493226P 20030807 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Kosson, Rosanne
LREP Knudsen, Peter J.
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 6218
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 120 OF 133 USPAT2 on STN
AN 2004:334808 USPAT2 <<LOGINID::20080129>>
TI Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7183379 B2 20070227
AI US 2004-882761 20040701 (10)
RLI Division of Ser. No. US 2001-29347, filed on 20 Dec 2001, Pat. No. US 6858407
PRAI US 2000-257774P 20001222 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Nashed, Nashaat T.
LREP D'Amico, Stephen C.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 14289
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 121 OF 133 USPAT2 on STN
AN   2004:274270 USPAT2 <<LOGINID::20080129>>
TI   Compositions and methods for enhanced mucosal delivery of Y2
       receptor-binding peptides and methods for treating and preventing
       obesity
IN   Quay, Steven C., Edmonds, WA, UNITED STATES
       Brandt, Gordon, Issaquah, WA, UNITED STATES
       Kleppe, Mary S., Kingston, WA, UNITED STATES
       MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA   Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S.
       corporation)
PI   US 7229966   B2 20070612
AI   US 2004-780325   20040217 (10)
RLI   Continuation of Ser. No. US 2003-745069, filed on 23 Dec 2003, PENDING
       Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002,
       PENDING
PRAI   US 2003-518812P   20031110 (60)
       US 2003-517290P   20031104 (60)
       US 2003-510785P   20031010 (60)
       US 2003-501170P   20030908 (60)
       US 2003-493226P   20030807 (60)
DT   Utility
FS   GRANTED
EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Kosson, Rosanne
LREP   Knudsen, Peter J.
CLMN   Number of Claims: 41
ECL   Exemplary Claim: 1
DRWN   23 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 6379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   Pharmaceutical compositions and methods are described comprising at
       least one Y2 receptor-binding peptide, such as peptide YY(PYY),
       Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal
       delivery-enhancing agents for enhanced nasal mucosal delivery of the
       peptide YY, for treating a variety of diseases and conditions in
       mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 122 OF 133 USPAT2 on STN
AN   2004:268264 USPAT2 <<LOGINID::20080129>>
TI   Compositions and methods for enhanced mucosal delivery of Y2
       receptor-binding peptides and methods for treating and preventing
       obesity
IN   Quay, Steven C., Edmonds, WA, UNITED STATES
       Brandt, Gordon, Issaquah, WA, UNITED STATES
       Kleppe, Mary S., Kingston, WA, UNITED STATES
       MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA   Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S.
       corporation)
PI   US 7157426   B2 20070102
AI   US 2004-768288   20040130 (10)
RLI   Continuation of Ser. No. US 2003-745069, filed on 23 Dec 2003, PENDING
       Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002,
       PENDING
PRAI   US 2003-518812P   20031110 (60)
       US 2003-517290P   20031104 (60)
       US 2003-510785P   20031010 (60)
       US 2003-501170P   20030908 (60)
       US 2003-493226P   20030807 (60)
DT   Utility

FS GRANTED
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Kosson, Rosanne
LREP Knudsen, Peter J.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 6114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 123 OF 133 USPAT2 on STN
AN 2004:203885 USPAT2 <<LOGINID::20080129>>
TI Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
IN Quay, Steven C., Edmonds, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
Kleppe, Mary S., Kingston, WA, UNITED STATES
MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc., Rothell, WA, UNITED STATES (U.S. corporation)
PI US 7186691 B2 20070306
AI US 2003-745069 20031223 (10)
RLI Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING
PRAI US 2003-518812P 20031110 (60)
US 2003-517290P 20031104 (60)
US 2003-510785P 20031010 (60)
US 2003-501170P 20030908 (60)
US 2003-493226P 20030807 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Kosson, Rosanne
LREP Knudsen, Peter J.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 6193
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 124 OF 133 USPAT2 on STN
AN 2004:150914 USPAT2 <<LOGINID::20080129>>
TI Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
IN Quay, Steven C, Edmonds, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S.

corporation)
PI US 7166575 B2 20070123
AI US 2002-322266 20021217 (10)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Kosson, Rosanne
LREP Knudsen, Peter J.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 12157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of peptide YY to the blood plasma or central nervous system (CNS) tissue or fluid, for example, by yielding a peak concentration (C.sub.max) of the peptide YY in the blood plasma or CNS tissue or fluid of the subject that is 20% or greater compared to a peak concentration of the peptide YY in the blood plasma or CNS tissue or fluid of the subject following administration to the subject of a same concentration or dose of the peptide YY to the subject by subcutaneous injection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 125 OF 133 USPAT2 on STN
AN 2004:77102 USPAT2 <<LOGINID::20080129>>
TI Ii-Key/antigenic epitope hybrid peptide vaccines
IN Humphreys, Robert E., Acton, MA, UNITED STATES
Xu, Minzhen, Northborough, MA, UNITED STATES
PA Antigen Express, Inc., Worcester, MA, UNITED STATES (U.S. corporation)
PI US 7179645 B2 20070220
AI US 2002-253286 20020924 (10)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Li, Q. Janice
LREP Pierce Atwood LLP, Farrell, Kevin M.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12901
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal

elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 126 OF 133 USPAT2 on STN
AN 2003:282745 USPAT2 <<LOGINID::20080129>>
TI Eubacterial minicells and their use as vectors for nucleic acid delivery and expression
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PA Vaxiion Therapeutics, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 7183105 B2 20070227
AI US 2002-156902 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, ABANDONED
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Woitach, Joseph; Assistant Examiner: Kelly, Robert M.
LREP Knobbe, Martens, Olson & Bear, LLP
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 21451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Th invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 127 OF 133 USPAT2 on STN
AN 2003:277136 USPAT2 <<LOGINID::20080129>>
TI Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Cheng, Janet D., Lawrenceville, NJ, UNITED STATES
PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7223558 B2 20070529
AI US 2002-193477 20020711 (10)
PRAI US 2002-372147P 20020412 (60)
US 2001-304888P 20010711 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: O'Hara, Eileen; Assistant Examiner: Hamud, Fozia
LREP Parlet, Nickki L., D'Amico, Stephen C.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 24 Drawing Figure(s); 24 Drawing Page(s)
LN.CNT 18656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding BGS-2, 3,

and 4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-2, 3, and 4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 128 OF 133 USPAT2 on STN
AN 2003:166515 USPAT2 <<LOGINID::20080129>>
TI Polynucleotides encoding novel cysteine proteases of the calpain superfamily, CAN-12v1 and CAN-12v2.
IN Chen, Jian, Princeton, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Vaz, Roy J., North Branch, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7186564 B2 20070306
AI US 2002-116519 20020403 (10)
PRAI US 2001-300620P 20010625 (60)
US 2001-296180P 20010606 (60)
US 2001-288768P 20010504 (60)
US 2001-281253P 20010403 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Nashed, Nashaat T.; Assistant Examiner: Moore, William W.
LREP D'Amico, Stephen C.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 27 Drawing Figure(s); 27 Drawing Page(s)
LN.CNT 30048
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding CAN-12 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of CAN-12 polypeptides, CAN-12v1 and CAN-12v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel CAN-12, CAN-12v1, and CAN-12v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly neuro- and musculo-degenerative conditions. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 129 OF 133 USPAT2 on STN
AN 2003:140506 USPAT2 <<LOGINID::20080129>>
TI Polynucleotides encoding a novel human G-protein coupled receptor splice variant HGPRBMY29sv1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES

Bol, David, Langhorne, PA, UNITED STATES
Hawken, Donald R., Lawrenceville, NJ, UNITED STATES
PA Bristol-Meyers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7049096 B2 20060523
AI US 2002-120604 20020411 (10)
PRAI US 2001-300619P 20010625 (60)
US 2001-288468P 20010503 (60)
US 2001-283145P 20010411 (60)
US 2001-283161P 20010411 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Landsman, Robert S.
LREP D'Amico, Stephen C.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 36 Drawing Figure(s); 36 Drawing Page(s)
LN.CNT 20151
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 130 OF 133 USPAT2 on STN
AN 2003:120301 USPAT2 <<LOGINID::20080129>>
TI Polynucleotides encoding a novel metalloprotease, MP-1
IN Chen, Jian, Princeton, NJ, United States
Feder, John N., Belle Mead, NJ, United States
Nelson, Thomas C., Lawrenceville, NJ, United States
Krystek, Stanley R., Ringoes, NJ, United States
Duclos, Franck, Washington Crossing, PA, United States
PA Bristol-Meyers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 6642041 B2 20031104
AI US 2002-67443 20020205 (10)
PRAI US 2001-226518P 20010205 (60)
US 2001-282814P 20010410 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Swope, Sheridan
LREP D'Amico, Stephen C.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 18 Drawing Figure(s); 18 Drawing Page(s)
LN.CNT 16160
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding MP-1

polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 131 OF 133 USPAT2 on STN
AN 2003:78525 USPAT2 <<LOGINID::20080129>>
TI Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
IN Chen, Jian, Princeton, NJ, UNITED STATES
Nelson, Thomas, Lawrenceville, NJ, UNITED STATES
Cheney, Daniel L., Flemington, NJ, UNITED STATES
PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7247717 B2 20070724
AI US 2001-993180 20011114 (9)
PRAI US 2000-248434P 20001114 (60)
US 2000-257610P 20001221 (60)
US 2001-282745P 20010410 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Nashed, Nashaat; Assistant Examiner: Moore, William W.
LREP D'Amico, Stephen C., Mangasarian, Karen, Loring, Denise L.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 14304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 132 OF 133 USPAT2 on STN
AN 2003:37516 USPAT2 <<LOGINID::20080129>>
TI Serine carboxypeptidase hx (SCPhx) and compositions thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA Serono Genetics Institute SA, FRANCE (non-U.S. corporation)
PI US 7074571 B2 20060711
AI US 2001-992600 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)

PI US 2001-293574P 20010525 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Myers, Carla J.
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 25479
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 133 OF 133 USPAT2 on STN
AN 2003:23722 USPAT2 <<LOGINID::20080129>>
TI Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
IN Feder, John N., Belle Mead, NJ, United States
Ramanathan, Chandra S., Wallingford, CT, United States
Mintier, Gabriel A., Hightstown, NJ, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 6858407 B2 20050222
AI US 2001-29347 20011220 (10)
PRAI US 2000-257774P 20001222 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Nashed, Nashaat T.
LREP D'Amico, Stephen C.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 14213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	472.75	472.96

FILE 'CAPLUS' ENTERED AT 11:21:12 ON 29 JAN 2008

FILE COVERS 1907 - 29 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 28 Jan 2008 (20080128/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s Reiner Roland/AU
L18   63 REINER ROLAND/AU

=> s l18 and alginate
         25949 ALGINATE
          2412 ALGINATES
         26636 ALGINATE
                 (ALGINATE OR ALGINATES)
L19   1 L18 AND ALGINATE

=> dis l19 bib abs

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
AN   2005:1173498 CAPLUS <<LOGINID::20080129>>
DN   143:427393
TI   Injectable crosslinked and non-crosslinked alginates for use in
     medicine and plastic surgery
IN   Reiner, Roland; Geigle, Peter; Gloeckner, Herma; Thuermer, Frank
PA   CellMed A.-G., Germany
SO   Ger. Offen., 9 pp.
     CODEN: GWXXBX
DT   Patent
LA   German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102004019241	A1	20051103	DE 2004-102004019241	20040416
	WO 2005105167	A1	20051110	WO 2005-EP2201	20050302

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,

```
             MR, NE, SN, TD, TG
     EP 1735020          A1    20061227    EP 2005-707688         20050302
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
     BR 2005009924       A     20070918    BR 2005-9924           20050302
     US 2007189114       A1    20070816    US 2007-679665         20070227
     US 2007179117       A1    20070802    US 2007-599980         20070403
PRAI DE 2004-102004019241 A     20040416
     WO 2004-EP9856      A1    20040903
     WO 2005-EP2201      W     20050302
AB   The invention concerns the use of crosslinked and non-crosslinked
     alginates as volume fillers in medicine and surgery for the
     treatment of wrinkles, bladder incontinence, vesicourethral and
     gastroesophageal reflux and the support of sphincter muscles.  Sodium or
     potassium alginate is crosslinked with calcium or barium ions;
     alginate and the cations can be dosed sep.
RE.CNT  11    THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s Geigle Peter/AU
L20          7 GEIGLE PETER/AU

=> dis l20 1-7 bib abs

L20  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2007:1398495  CAPLUS <<LOGINID::20080129>>
TI   Cultivation and differentiation of encapsulated hMSC-TERT in a disposable
     small-scale syringe-like fixed bed reactor
AU   Weber, Christian; Pohl, Sebastian; Poertner, Ralf; Wallrapp, Christine;
     Kassem, Moustapha; Geigle, Peter; Czermak, Peter
CS   Institute of Biopharmaceutical Technology, University of Applied Sciences
     Giessen-Friedberg, Giessen, Germany
SO   Open Biomedical Engineering Journal (2007), 1, 64-70
     CODEN: OBEJA6; ISSN: 1874-1207
     URL:
http://www.bentham-open.org/pages/gen.php?file=64TOBEJ.pdf
&PHPSESSID=
     7413d61ccbe1a4ba77483294f60a68ba
PB   Bentham Science Publishers Ltd.
DT   Journal; (online computer file)
LA   English
AB   The use of com. available plastic syringes is introduced as disposable
     small-scale fixed bed bioreactors for the cultivation of implantable
     therapeutic cell systems on the basis of an alginate-encapsulated human
     mesenchymal stem cell line.  The system introduced is fitted with a
     noninvasive oxygen sensor for the continuous monitoring of the cultivation
     process.  Fixed bed bioreactors offer advantages in comparison to other
     systems due to their ease of automation and online monitoring capability
     during the cultivation process.  These benefits combined with the
     advantage of single-use make the fixed bed reactor an interesting option
     for GMP processes.  The cultivation of the encapsulated cells in the fixed
     bed bioreactor system offered vitalities and adipogenic differentiation
     similar to well-mixed suspension cultures.

L20  ANSWER 2 OF 7  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2007:1398493  CAPLUS <<LOGINID::20080129>>
TI   Expansion and harvesting of hMSC-TERT
AU   Weber, Christian; Pohl, Sebastian; Poertner, Ralf; Wallrapp, Christine;
     Kassem, Moustapha; Geigle, Peter; Czermak, Peter
CS   Institute of Biopharmaceutical Technology, University of Applied Sciences
```

Giessen-Friedberg, Giessen, Germany
SO Open Biomedical Engineering Journal (2007), 1, 38-46
CODEN: OBEJA6; ISSN: 1874-1207
URL:
http://www.bentham-open.org/pages/gen.php?file=38TOBEJ.pdf
&PHPSESSID=
7413d61ccbe1a4ba77483294f60a68ba
PB Bentham Science Publishers Ltd.
DT Journal; (online computer file)
LA English
AB The expansion of human mesenchymal stem cells as suspension culture by means of spinner flasks and microcarriers, compared to the cultivation in tissue culture flasks, offers the advantage of reducing the requirements of large incubator capacities as well as reducing the handling effort during cultivation and harvesting. Nonporous microcarriers are preferable when the cells need to be kept in viable condition for further applications like tissue engineering or cell therapy. In this study, the qualification of Biosilon, Cytodex 1, Cytodex 3, RapidCell and P102-L for expansion of hMSC-TERT with an associated harvesting process using either trypsin, accutase, collagenase or a trypsin-accutase mixture was investigated. A subsequent adipogenic differentiation of harvested hMSC-TERT was performed in order to observe possible neg. effects on their (adipogenic) differentiation potential as a result of the cultivation and harvesting method. The cultivated cells showed an average growth rate of 0.52 d-1. The cells cultivated on Biosilon, RapidCell and P102-L were harvested succesfully achieving high cell yield and vitalities near 100%. This was not the case for cells on Cytodex 1 and Cytodex 3. The trypsin-accutase mix was most effective. After spinner expansion and harvesting the cells were successfully differentiated to adipocytes.

L20 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1303151 CAPLUS <<LOGINID::20080129>>
DN 147:548045
TI Spherical microcapsules comprising human mesenchymal stem cells expressing and secreting GLP-1 peptides and uses in treating diabetes
IN Geigle, Peter; Wallrapp, Christine; Thoenes, Eric; Thuermer, Frank
PA Biocompatibles UK Ltd., UK
SO PCT Int. Appl., 95pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007128443	A2	20071115	WO 2007-EP3775	20070427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1854455	A1	20071114	EP 2006-9678	20060510
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,				

BA, HR, MK, YU
PRAI EP 2006-9678 A 20060510
OS MARPAT 147:548045
AB The present invention provides spherical microcapsules comprising at least one surface coating and a core, wherein the at least one surface coating comprises cross-linked polymers, and wherein the core comprises cross-linked polymers and cells capable of expressing and secreting a GLP-1 peptide, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof. The present application is furthermore directed to methods for production of these spherical microcapsules and to the use of these microcapsules e.g. in the treatment of type 2 diabetes, weight disorders, neurodegenerative disorders or for the treatment of disorders and diseases or conditions associated to apoptosis. The cells contained in the core of the spherical microcapsule are selected from human mesenchymal stem cells, differentiated cells derived from human mesenchymal stem cells, including osteoblasts, chondrocytes, fat cells (adipocytes), or neuron-like cells including brain cells.

L20 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:355992 CAPLUS <<LOGINID::20080129>>
DN 146:351951
TI Glp-1 (glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
IN Geigle, Peter; Wallrapp, Christine; Thoenes, Eric
PA Biocompatibles UK Limited, UK
SO Eur. Pat. Appl., 55pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1767545	A1	20070328	EP 2005-20718	20050922
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
WO 2007039140	A1	20070412	WO 2006-EP9226	20060922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI EP 2005-20718 A 20050922
AB The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various

diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:492867 CAPLUS <<LOGINID::20080129>>
DN 144:475079
TI Method for the preparation of double-layered or multilayered microcapsules with cells
IN Thoenes, Eric; Geigle, Peter
PA CellMed A.-G., Germany
SO Ger. Offen., 7 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 102004055729	A1	20060524	DE 2004-102004055729	20041118
CA 2588509	A1	20060526	CA 2005-2588509	20050922
WO 2006053604	A1	20060526	WO 2005-EP10277	20050922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1811978	A1	20070801	EP 2005-786032	20050922
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI DE 2004-102004055729	A	20041118		
WO 2005-EP10277	W	20050922		

AB The invention concerns a method for the preparation double-layered or multi-layered microcapsules that are composed of microcapsule that include an inner layer and one or more outer layers; the inner layer is prepared from a crosslinked polymer and the cells; the outer layer(s) contain the same polymer but no cells. The microcapsules can be used for transplantation. The encapsulation method can also be used for other biol. active substances, e.g. drugs, cytostatics, dietary supplements instead of cells.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1173498 CAPLUS <<LOGINID::20080129>>
DN 143:427393
TI Injectable crosslinked and non-crosslinked alginates for use in medicine and plastic surgery
IN Reiner, Roland; Geigle, Peter; Gloeckner, Herma; Thuermer, Frank
PA CellMed A.-G., Germany
SO Ger. Offen., 9 pp.
CODEN: GWXXBX
DT Patent
LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102004019241	A1	20051103	DE 2004-102004019241	20040416
	WO 2005105167	A1	20051110	WO 2005-EP2201	20050302
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1735020	A1	20061227	EP 2005-707688	20050302
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	BR 2005009924	A	20070918	BR 2005-9924	20050302
	US 2007189114	A1	20070816	US 2007-679665	20070227
	US 2007179117	A1	20070802	US 2007-599980	20070403
PRAI	DE 2004-102004019241	A	20040416		
	WO 2004-EP9856	A1	20040903		
	WO 2005-EP2201	W	20050302		

AB The invention concerns the use of crosslinked and non-crosslinked alginates as volume fillers in medicine and surgery for the treatment of wrinkles, bladder incontinence, vesicourethral and gastroesophageal reflux and the support of sphincter muscles. Sodium or potassium alginate is crosslinked with calcium or barium ions; alginate and the cations can be dosed sep.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:830598 CAPLUS <<LOGINID::20080129>>
TI Procedures for operate a centrifugation unit, as well asznetrifugiereinhe it to accomplish such a procedure [Machine Translation].
IN Geigle, Peter
PA Geigle, Peter, Dr., 63755 Alzenau, De, Germany
SO Ger. Offen., No pp. given
CODEN: GWXXBX
DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19746914	A1	19980610	DE 1997-19746914	19971023
	DE 19746914	C2	19990722		
	CA 2269607	A1	19980507	CA 1997-2269607	19971024
	CA 2269607	C	20040323		
	EP 934031	B1	20020918	EP 1997-912216	19971024
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	AT 224214	T	20021015	AT 1997-912216	19971024
	ES 2184067	T3	20030401	ES 1997-912216	19971024
PRAI	DE 1996-19644336	A1	19961025		
	WO 1997-EP5865	W	19971024		

AB Unavailable

=> s Glockner Herma/AU

```
L21          2 GLOCKNER HERMA/AU

=> dis l21 1-2 bib abs

L21  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2000:646174  CAPLUS <<LOGINID::20080129>>
DN   133:247248
TI   Method and device for the in vitro testing of active substances
IN   Glockner, Herma; Lemke, Horst-Dieter; Meyer, Christoph
PA   Akzo Nobel NV, Neth.
SO   PCT Int. Appl., 41 pp.
     CODEN: PIXXD2
DT   Patent
LA   German
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2000053797        A1    20000914    WO 2000-EP2011         20000308
         W:  JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
     EP 1159443           A1    20011205    EP 2000-907670         20000308
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2002537851        T     20021112    JP 2000-603418         20000308
PRAI DE 1999-19910540     A     19990309
     WO 2000-EP2011       W     20000308
AB   The invention discloses a method for the in vitro testing of active
     substances (e.g. cytostatic agents) in cells which includes at least the
     following steps: provision of a cell culture dish having an inner chamber
     and an outer wall as well as a first and a second membrane system
     positioned in the inner chamber, a cell culture chamber being configured
     between the membrane systems and the inner wall of the inner chamber;
     introduction of a cell culture and a cell culture medium into the cell
     culture chamber; addition of a liquid nutrient medium to the cell culture
     chamber; removal of products of metabolism by means of the first membrane
     system; delivery of at least one gaseous medium to the cell culture
     chamber by means of the second membrane system; addition of at least one
     active substance into the cell culture chamber in accordance with a set
     active substance concentration-time curve; and monitoring of cell vitality.
The
     invention also provides a device for performing the method.  Use of the
     device for testing the effect of idarubicin on the leukemic cell line CCRF
     CEM is described.
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2000:646173  CAPLUS <<LOGINID::20080129>>
DN   133:205071
TI   Membrane module for testing the activity of drugs on patient-specific
     tumor cells
IN   Glockner, Herma; Lemke, Horst-Dieter; Hauck, Friedrich;
     Zimmerer, Christoph; Wollbeck, Rudi
PA   Akzo Nobel NV, Neth.
SO   PCT Int. Appl., 24 pp.
     CODEN: PIXXD2
DT   Patent
LA   German
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
```

```
     ---------------     ----   --------    --------------------   --------
PI   WO 2000053796        A1    20000914    WO 2000-EP1819         20000302
         W:  JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
     EP 1159444           A1    20011205    EP 2000-916893         20000302
     EP 1159444           B1    20040526
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2002537850        T     20021112    JP 2000-603417         20000302
     AT 267875            T     20040615    AT 2000-916893         20000302
     ES 2220443           T3    20041216    ES 2000-916893         20000302
PRAI DE 1999-19910539     A     19990309
     WO 2000-EP1819       W     20000302
AB   The invention relates to a membrane module for testing active substances
     at cells, e.g. the screening of antitumor agents on tumor cells isolated
     from a patient.  The membrane module comprises an interior space which is
     defined by a lid, a bottom and a side wall and houses the cell culture.  A
     system of first capillary membranes and a system of second capillary
     membranes and optionally addnl. systems of capillary membranes are
     arranged therein.  The capillary membranes in the interior space are
     arranged in at least one two-dimensional layer that is parallel to the
     bottom.  A cell culturing room is configured in the interior space in the
     extracapillary space around the capillary membranes.  The capillary
     membranes are provided with a lumen resp. that can be charged with a
     fluid.  At least one end of the capillary membranes goes through the side
     wall of the interior space resp., is separated according to systems and is
     embedded into the casting compound and in such a way that the interior space
     is sealed off from the exterior in a fluid-proof manner.  The capillary
     membranes of each system are fluidly connected to the lumens thereof via
     an inlet (7) and/or an outlet.  The interior space has a volume between 0.1
     and 5 cm3.
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s Thurmer Frank/AU
L22           2 THURMER FRANK/AU

=> dis l22 1-2 bib abs

L22  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2002:209132  CAPLUS <<LOGINID::20080129>>
DN   137:237501
TI   Microencapsulation-based cell therapy
AU   Zimmermann, Ulrich; Cramer, Hubert; Jork, Anette; Thurmer, Frank
     ; Zimmermann, Heiko; Fuhr, Gunter; Hasse, Christian; Rothmund, Matthias
CS   Lehrstuhl fur Biotechnologie Universitat Wurzburg Am Hubland Biozentrum,
     Wurzburg, D-97074, Germany
SO   Biotechnology (2nd Edition) (2001), Volume 10, 547-571.  Editor(s): Rehm,
     Hans-Juergen. Publisher: Wiley-VCH Verlag GmbH, Weinheim, Germany.
     CODEN: 58AHA6
DT   Conference; General Review
LA   English
AB   A review.  The article focuses on the formulation of alginate-based
     immunoisolation system for encapsulated cell therapy.
RE.CNT  123   THERE ARE 123 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2002:76857  CAPLUS <<LOGINID::20080129>>
```

DN 137:190568
TI A novel class of amitogenic alginate microcapsules for long-term immunoisolated transplantation
AU Zimmermann, Ulrich; Thurmer, Frank; Jork, Anette; Weber, Meike; Mimietz, Saskia; Hillgartner, Markus; Brunnenmeier, Frank; Zimmermann, Heiko; Westphal, Ines; Fuhr, Gunter; Noth, Ulrike; Haase, Axel; Steinert, Andre; Hendrich, Christian
CS Lehrstuhl fur Biotechnologie, Universitat Wurzburg, Wurzburg, D-97074, Germany
SO Annals of the New York Academy of Sciences (2001), 944(Bioartificial Organs III), 199-215
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal
LA English
AB In the light of results of clin. trials with immunoisolated human parathyroid tissue Ba2+-alginate capsules were developed that meet the requirements for long-term immunoisolated transplantation of (allogeneic and xenogeneic) cells and tissue fragments. Biocompatibility of the capsules was achieved by subjecting high-M alginate extracted from freshly collected brown algae to a simple purification protocol that removes quant. mitogenic and cytotoxic impurities without degradation of the alginate polymers. The final ultra-high-viscosity, clin.-grade (UHV/CG) product did not evoke any (significant) foreign body reaction in BB rats or in baboons. Similarly, the very sensitive pERK assay did not reveal any mitogenic impurities. Encapsulated cells also exhibited excellent secretory properties under in vitro conditions. Despite biocompatible material, pericapsular fibrosis is also induced by imperfect capsule surfaces that can favor cell attachment and migration under the release of material traces. This material can interact with free end monomers of the alginate polymers under formation of mitogenic advanced glycation products. Smooth surfaces, and thus topog. biocompatibility of the capsules (visualized by atomic force microscopy), can be generated by appropriate crosslinking of the UHV/CG-alginate with Ba2+ and simultaneous suppression of capsule swelling by incorporation of proteins and/or perfluorocarbons (i.e., medically approved compds. with high oxygen capacity). Perfluorocarbon-loaded alginate capsules allow long-term non-invasive monitoring of the location and the oxygen supply of the transplants by using 19F-MRI. Transplantation studies in rats demonstrated that these capsules were functional over a period of more than two years.
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis hist

(FILE 'HOME' ENTERED AT 11:00:15 ON 29 JAN 2008)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT, NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPATOLD, USPAT2, WPIFV, WPINDEX, WSCA, WTEXTILES, BIOSIS, EMBASE, MEDLINE' ENTERED AT 11:00:37 ON 29 JAN 2008
L1 162242 S ALGINATE
L2 45390 S L1 AND TISSUE
L3 28965 S L2 AND (AUGMENT? OR VOLUME)
L4 26601 S L3 AND INCREAS?
L5 11750 S L4 AND (CROSS(A)LINK?)
L6 2611 S L5 AND MICROPARTIC?
L7 2357 S L6 AND (CALCIUM OR BARIUM)
L8 2094 S L7 AND (SKIN OR MUSCLE OR SPHINCTER)

```
L9          1794 S L8 AND (EDTA OR CITRATE)
L10         1767 S L9 AND GEL
L11          800 S L9 AND HYDROGEL
L12          501 S L11 AND (SUBCUTANEOUS(S)INJECTION)
L13          133 S L12 AND (ADHESION(S)PEPTIDE)
L14          421 S L12 AND (ANTIBIOTIC OR STREPTOMYCIN)
L15          400 S L14 AND (ENGINEER? OR REPLACEMENT)
L16          333 S L15 AND ADHESION
L17           21 S L16 AND URON?

     FILE 'CAPLUS' ENTERED AT 11:21:12 ON 29 JAN 2008
L18           63 S REINER ROLAND/AU
L19            1 S L18 AND ALGINATE
L20            7 S GEIGLE PETER/AU
L21            2 S GLOCKNER HERMA/AU
L22            2 S THURMER FRANK/AU

=>

---Logging off of STN---



=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY    SESSION
FULL ESTIMATED COST                               46.22     519.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                  ENTRY    SESSION
CA SUBSCRIBER PRICE                               -8.80      -8.80

STN INTERNATIONAL LOGOFF AT 11:24:03 ON 29 JAN 2008



Connecting via Winsock to STN at pto-stn on port 23



Welcome to STN International!  Enter x:X

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1  OCT 11  Instructor-led and self paced STN learning resources
                  available at https://cas.csod.com/Default.aspx?c=001
 NEWS  2  JAN 24  The new and enhanced DPCI file on STN has been released
 NEWS  3  JAN 26  Improved Timeliness of CAS Indexing Adds Value to
                  USPATFULL and USPAT2 Chemistry Patents
```

NEWS 4 JAN 26 Updated MeSH vocabulary, new structured abstracts, and other enhancements improve searching in STN reload of MEDLINE
NEWS 5 JAN 28 CABA will be updated weekly
NEWS 6 FEB 23 PCTFULL file on STN completely reloaded
NEWS 7 FEB 23 STN AnaVist Test Projects Now Available for Qualified Customers
NEWS 8 FEB 25 LPCI will be replaced by LDPCI
NEWS 9 MAR 07 Pricing for SELECTing Patent, Application, and Priority Numbers in the USPAT and IFI Database Families is Now Consistent with Similar Patent Databases on STN
NEWS 10 APR 26 Expanded Swedish Patent Application Coverage in CA/CAplus Provides More Current and Complete Information
NEWS 11 APR 28 The DWPI (files WPINDEX, WPIDS and WPIX) on STN have been enhanced with thesauri for the European Patent Classifications
NEWS 12 MAY 02 MEDLINE Improvements Provide Fast and Simple Access to DOI and Chemical Name Information
NEWS 13 MAY 12 European Patent Classification thesauri added to the INPADOC files, PCTFULL, GBFULL and FRFULL
NEWS 14 MAY 23 Enhanced performance of STN biosequence searches
NEWS 15 MAY 23 Free Trial of the Numeric Property Search Feature in PCTFULL on STN
NEWS 16 JUN 20 STN on the Web Enhanced with New Patent Family Assistant and Updated Structure Plug-In
NEWS 17 JUN 20 INPADOC databases enhanced with first page images
NEWS 18 JUN 20 PATDPA database updates to end in June 2011
NEWS 19 JUN 26 MARPAT Enhancements Save Time and Increase Usability
NEWS 20 JUL 25 STN adds Australian patent full-text database, AUPATFULL, including the new numeric search feature.
NEWS 21 AUG 01 CA Sections Added to ACS Publications Web Editions Platform
NEWS 22 AUG 16 INPADOC: Coverage of German Patent Data resumed, enhanced legal status
NEWS 23 AUG 18 Upgrade now to STN Express, Version 8.5
NEWS 24 SEP 01 CAS Journal Coverage Now Includes Ahead-of-Print Articles for More Than 100 Journal Titles
NEWS 25 SEP 01 Older Versions of STN Express to be Discontinued Beginning in March 2012
NEWS 26 SEP 09 USAN Database Updates Offer Superior Currency on STN(R)
NEWS 27 SEP 26 STN Adds Canadian Patent Full-text Database - CANPATFULL
NEWS 28 SEP 26 GEOREF and ENCOMPLIT databases were reloaded on September 24, 2011.
NEWS 29 SEP 26 Updates to the IFIPAT/IFIUDB/IFICDB databases have resumed.
NEWS 30 SEP 26 ECLA Thesaurus in CA/CAplus Improves Patent Searching on STN
NEWS 31 SEP 26 Access AUPATFULL and CANPATFULL databases with STN Viewer
NEWS 32 OCT 26 New STN Revolutionizes Patent Searching for Professionals

NEWS EXPRESS 18 AUGUST 2011 CURRENT WINDOWS VERSION IS V8.5,
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2011.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS TRAINING Find instructor-led and self-directed training opportunities

Enter NEWS followed by the item number or name to see news on that specific topic.

products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:44:17 ON 15 NOV 2011

=> file polymer medline biosis embase
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.23	0.23

FILE 'APOLLIT' ENTERED AT 10:44:35 ON 15 NOV 2011
COPYRIGHT (c) 2011 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 10:44:35 ON 15 NOV 2011
COPYRIGHT (c) 2011 Elsevier Properties SA. ALL rights reserved

FILE 'CAPLUS' ENTERED AT 10:44:35 ON 15 NOV 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 10:44:35 ON 15 NOV 2011
COPYRIGHT (c) 2011 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 10:44:35 ON 15 NOV 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 10:44:35 ON 15 NOV 2011
Compendex Compilation and Indexing (C) 2011
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 10:44:35 ON 15 NOV 2011
COPYRIGHT (C) 2011 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 10:44:35 ON 15 NOV 2011
COPYRIGHT (C) 2011 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 10:44:35 ON 15 NOV 2011
COPYRIGHT (C) 2011 IFI CLAIMS(R) Patent Services (IFI)

FILE 'NTIS' ENTERED AT 10:44:35 ON 15 NOV 2011
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2011)

FILE 'PASCAL' ENTERED AT 10:44:35 ON 15 NOV 2011
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2011 INIST-CNRS. All rights reserved.

FILE 'RAPRA' ENTERED AT 10:44:35 ON 15 NOV 2011
COPYRIGHT (C) 2011 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 10:44:35 ON 15 NOV 2011
Copyright (c) 2011 The Thomson Corporation

```
FILE 'USPATFULL' ENTERED AT 10:44:35 ON 15 NOV 2011
CA INDEXING COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 10:44:35 ON 15 NOV 2011
CA INDEXING COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:44:35 ON 15 NOV 2011
CA INDEXING COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 10:44:35 ON 15 NOV 2011
COPYRIGHT (C) 2011 THOMSON REUTERS

FILE 'WSCA' ENTERED AT 10:44:35 ON 15 NOV 2011
COPYRIGHT (C) 2011 PAINT RESEARCH

FILE 'MEDLINE' ENTERED AT 10:44:35 ON 15 NOV 2011

FILE 'BIOSIS' ENTERED AT 10:44:35 ON 15 NOV 2011
Copyright (c) 2011 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 10:44:35 ON 15 NOV 2011
Copyright (c) 2011 Elsevier B.V. All rights reserved.

=> s alginate
L1      235563 ALGINATE

=> s l1 and crosslink?
L2       35069 L1 AND CROSSLINK?

=> s l2 and (barium or calcium)
L3       24186 L2 AND (BARIUM OR CALCIUM)

=> s l3 and (molecular (a) weight)
  14 FILES SEARCHED...
L4       14887 L3 AND (MOLECULAR (A) WEIGHT)

=> s l4 and kDa
L5        3112 L4 AND KDA

=> s l5 and ((tissue(a)volume) or (tissue(a)augment?))
  19 FILES SEARCHED...
L6         142 L5 AND ((TISSUE(A) VOLUME) OR (TISSUE(A) AUGMENT?))

=> s l6 and (skin or muscle or sphincter or bladder)
L7         139 L6 AND (SKIN OR MUSCLE OR SPHINCTER OR BLADDER)

=> l7 and (gel or microparticles)
L7 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l7 and (gel or microparticles)
L8         138 L7 AND (GEL OR MICROPARTICLES)

=> s l8 and buffer
L9         131 L8 AND BUFFER
```

```
=> s l9 and citrate
L10         94 L9 AND CITRATE

=> s l10 and EDTA
L11         75 L10 AND EDTA

=> dis l11 1-75 bib abs

L11  ANSWER 1 OF 75  USPATFULL on STN
AN     2011:280484  USPATFULL <<LOGINID::20111115>>
TI     Visual Assays for Coatings Incorporating Bioactive Enzymes for Catalytic
       Functions
IN     Williams, Eric B., Petal, MS, UNITED STATES
       Braasch, Dwaine, Hattiesburg, MS, UNITED STATES
       Rawlins, James W., Petal, MS, UNITED STATES
       Wales, Melinda, Bryan, TX, UNITED STATES
       McDaniel, C. Steven, Austin, TX, UNITED STATES
PA     REACTIVE SURFACES, LTD., Austin, TX, UNITED STATES (U.S. corporation)
PI     US 20110250626      A1  20111013
AI     US 2011-85061       A1  20110412 (13)
RLI    Continuation-in-part of Ser. No. US 2011-69864, filed on 23 Mar 2011,
       PENDING Continuation-in-part of Ser. No. US 2011-4279, filed on 11 Jan
       2011, PENDING Continuation-in-part of Ser. No. US 2009-474921, filed on
       29 May 2009, PENDING Continuation-in-part of Ser. No. US 2004-884355,
       filed on 2 Jul 2004, PENDING Continuation-in-part of Ser. No. US
       2008-243755, filed on 1 Oct 2008, PENDING Continuation-in-part of Ser.
       No. US 2003-655345, filed on 4 Sep 2003, PENDING
PRAI   US 2010-322910P         20100412 (61)
       US 2010-316504P         20100323 (61)
       US 2010-293897P         20100111 (61)
       US 2008-57705P          20080530 (61)
       US 2008-58025P          20080602 (61)
       US 2003-485234P         20030703 (60)
       US 2007-976676P         20071001 (60)
       US 2002-409102P         20020909 (60)
DT     Utility
FS     APPLICATION
CLMN   Number of Claims: 20
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 35268
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Disclosed herein are materials such as a coating, comprising a lipolytic
       enzyme or organophosphrous compound degrading enzyme. Also disclosed
       herein are methods of visually detecting enzyme activity in a coating by
       contacting the coating with a substrate of an enzyme and a visual
       indicator that changes appearance upon production of a product of enzyme
       activity on a tack-free coating surface.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 2 OF 75  USPATFULL on STN
AN     2011:269225  USPATFULL <<LOGINID::20111115>>
TI     Polymeric Coatings Incorporating Bioactive Enzymes for Cleaning a
       Surface
IN     Wales, Melinda, Bryan, TX, UNITED STATES
       McDaniel, C. Steven, Austin, TX, UNITED STATES
PA     REACTIVE SURFACES, LTD., Austin, TX, UNITED STATES (U.S. corporation)
PI     US 20110240064      A1  20111006
AI     US 2011-69864       A1  20110323 (13)
RLI    Continuation-in-part of Ser. No. US 2009-474921, filed on 29 May 2009,
```

PENDING Continuation-in-part of Ser. No. US 2004-884355, filed on 2 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2008-243755, filed on 1 Oct 2008, PENDING Continuation-in-part of Ser. No. US 2003-655345, filed on 4 Sep 2003, PENDING Continuation-in-part of Ser. No. US 2011-4279, filed on 11 Jan 2011, PENDING
PRAI US 2010-316504P 20100323 (61)
US 2008-57705P 20080530 (61)
US 2008-58025P 20080602 (61)
US 2003-485234P 20030703 (60)
US 2007-976676P 20071001 (60)
US 2002-409102P 20020909 (60)
US 2010-293897P 20100111 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 34670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are a materials such as a coating, such as an architectural coating or a CARC coating, comprising a lipolytic enzyme or organophosphorous compound degrading enzyme. Also disclosed herein are methods of decontaminating a surface comprising such a material from a chemical substrate of an enzyme such as a lipid or an organophosphorus compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 75 USPATFULL on STN
AN 2010:301276 USPATFULL <<LOGINID::20111115>>
TI ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Mountain View, CA, UNITED STATES
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20100268288 A1 20101021
AI US 2010-703679 A1 20100210 (12)
RLI Continuation of Ser. No. US 2004-998351, filed on 26 Nov 2004, ABANDONED Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, ABANDONED Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, ABANDONED
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 14692
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L11 ANSWER 4 OF 75 USPATFULL on STN
AN 2010:236647 USPATFULL <<LOGINID::20111115>>
TI Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes
IN McDaniel, C. Steven, Austin, TX, UNITED STATES
Wales, Melinda E., Bryan, TX, UNITED STATES
Rawlins, James, Hattiesburg, MS, UNITED STATES
Cipi, Pirro, Hattiesburg, MS, UNITED STATES
Williams, Eric, Petal, MS, UNITED STATES
Carvajal, Juan Carlo, Austin, TX, UNITED STATES
PA REACTIVE SURFACES, LTD., Austin, TX, UNITED STATES (U.S. corporation)
PI US 20100210745 A1 20100819
AI US 2010-696651 A1 20100129 (12)
RLI Continuation-in-part of Ser. No. US 2009-474921, filed on 29 May 2009, PENDING Continuation-in-part of Ser. No. US 2004-884355, filed on 2 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2008-243755, filed on 1 Oct 2008, PENDING Continuation-in-part of Ser. No. US 2003-655345, filed on 4 Sep 2003, PENDING
PRAI US 2009-148502P 20090130 (61)
US 2008-57705P 20080530 (61)
US 2008-58025P 20080602 (61)
US 2003-485234P 20030703 (60)
US 2007-976676P 20071001 (60)
US 2002-409102P 20020909 (60)
DT Utility
FS APPLICATION
LREP C. Steven McDaniel, c/o Daffer McDaniel LLP, P.O. Box 684908, Austin, TX, 78768-4908, US
CLMN Number of Claims: 108
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 37946
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are polymeric materials such as a coating, a plastic, a laminate, a composite, an elastomer, an adhesive, or a sealant; a surface treatment such as a textile finish or a wax; a filler for such a polymeric material or a surface treatment that includes an enzyme such as an esterase (e.g., a lipolytic enzyme, a sulfuric ester hydrolase, an organophosphorus compound degradation enzyme), an enzyme (e.g., a lysozyme, a lytic transglycosylase) that degrades a cell wall and/or a cell membrane component, a biocidal or biostatic peotide, and/or a peptidase. Also disclosed herein are methods of altering a material's property such as service life, flexability, or rigidity, by incorporation of an enzyme into a material capable of being chemically crosslinked by the activity of a lipolytic enzyme, a hydrolase, and/or a urease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 75 USPATFULL on STN
AN 2010:154387 USPATFULL <<LOGINID::20111115>>
TI IMIDATED BIOPOLYMER ADHESIVE AND HYDROGEL
IN Elisseeff, Jennifer H., Baltimore, MD, UNITED STATES
Strehin, Iossif A., Baltimore, MD, UNITED STATES
PA THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD, UNITED STATES (U.S. corporation)
PI US 20100137241 A1 20100603
AI US 2007-517672 A1 20071204 (12)
WO 2007-US86334 20071204
20091215 PCT 371 date

PRAI US 2006-868459P 20061204 (60)
DT Utility
FS APPLICATION
LREP EDWARDS ANGELL PALMER & DODGE LLP, P.O. BOX
55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 2147
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Biologically compatible polymers carry an imide and can be used as an adhesive, a hydrogel or both. A second biologically compatible polymer reactive with the imidated polymer can be used therewith to seal openings.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 75 USPATFULL on STN
AN 2010:145785 USPATFULL <<LOGINID::20111115>>
TI Electrospun Cell Matrices
IN Atala, Anthony, Winston Salem, NC, UNITED STATES
Yoo, James, Winston Salem, NC, UNITED STATES
Lim, Grace, Winston-Salem, NC, UNITED STATES
Czerw, Richard, Clemmons, NC, UNITED STATES
Soker, Shay, Greensboro, NC, UNITED STATES
Stitzel, Joel, Winston-Salem, NC, UNITED STATES
PA Wake Forest University Health Sciences, Winston-Salem, NC, UNITED STATES (U.S. corporation)
PI US 20100129450 A1 20100527
AI US 2009-621052 A1 20091118 (12)
RLI Continuation of Ser. No. US 2005-83853, filed on 18 Mar 2005, ABANDONED
PRAI US 2005-660832P 20050311 (60)
DT Utility
FS APPLICATION
LREP NUTTER MCCLENNEN & FISH LLP, SEAPORT WEST, 155
SEAPORT BOULEVARD,
BOSTON, MA, 02210-2604, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1-16
DRWN 10 Drawing Page(s)
LN.CNT 2587
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to compositions and methods for preparing electrospun matrices comprising at least one natural biological material component and at least one synthetic polymer material. The natural component makes the matrices highly biocompatible while the molecular weight polymer component can impart additional strength mechanical strength to the scaffold and/or improve ease of manufacture by increasing viscosity and spinning characteristics of the solution during electrospining.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 75 USPATFULL on STN
AN 2010:103970 USPATFULL <<LOGINID::20111115>>
TI IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Mountain View, CA, UNITED STATES
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20100092536 A1 20100415
AI US 2009-464012 A1 20090511 (12)
RLI Continuation of Ser. No. US 2004-1789, filed on 1 Dec 2004, ABANDONED Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, ABANDONED Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, ABANDONED Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, ABANDONED
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 14999
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 75 USPATFULL on STN
AN 2010:90634 USPATFULL <<LOGINID::20111115>>
TI ALGINATE AND ALGINATE LYASE COMPOSITIONS AND METHODS OF USE
IN Barnett, Bradley P., Baltimore, MD, UNITED STATES
Gailloud, Philippe, Towson, MD, UNITED STATES
PA THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD, UNITED STATES (U.S. corporation)
PI US 20100080788 A1 20100401
AI US 2009-422637 A1 20090413 (12)
RLI Continuation of Ser. No. WO 2007-US21872, filed on 11 Oct 2007, PENDING
PRAI US 2006-851837P 20061012 (60)
US 2007-936230P 20070619 (60)
DT Utility
FS APPLICATION
LREP EDWARDS ANGELL PALMER & DODGE LLP, P.O. BOX
55874, BOSTON, MA, 02205, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 4197
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features alginate and alginate lyase compositions and methods that are useful for the treatment of various conditions and diseases. The invention also provides kits and instructions for use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 75 USPATFULL on STN
AN 2010:61863 USPATFULL <<LOGINID::20111115>>
TI HYDROGELS FOR VOCAL CORD AND SOFT TISSUE AUGMENTATION AND REPAIR
IN Zeitels, Steven M., Newton, MA, UNITED STATES
Hillman, Robert Edward, Weston, MA, UNITED STATES

Karajanagi, Sandeep Sidram, Malden, MA, UNITED STATES
Langer, Robert S., Newton, MA, UNITED STATES
PI US 20100055184 A1 20100304
AI US 2009-553800 A1 20090903 (12)
PRAI US 2008-94237P 20080904 (61)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, P.C., 600 ATLANTIC AVENUE,
BOSTON, MA,
02210-2206, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides hydrogels and compositions thereof for vocal cord repair or augmentation, as well as other soft tissue repair or augmentation (e.g., bladder neck augmentation, dermal fillers, breast implants, intervertebral disks, muscle-mass). The hydrogels or compositions thereof are injected into the superficial lamina propria or phonatory epithelium to restore the phonatory mucosa of the vocal cords, thereby restoring a patient's voice. In particular, it has been discovered that hydrogels with an elastic shear modulus of approximately 25 Pa are useful in restoring the pliability of the phonatory mucosa. The invention also provides methods of preparing and using the inventive hydrogels.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 75 USPATFULL on STN
AN 2009:239288 USPATFULL <<LOGINID::20111115>>
TI SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Mountain View, CA, UNITED STATES
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20090214652 A1 20090827
AI US 2009-425316 A1 20090416 (12)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, ABANDONED Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, ABANDONED Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, ABANDONED
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 12543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is

placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 75 USPATFULL on STN
AN 2009:207126 USPATFULL <<LOGINID::20111115>>
TI ISOLATING AND PURIFYING CELLS FOR THERAPY
IN Tillman, Bryan, Lewisville, NC, UNITED STATES
Atala, Anthony, Winston Salem, NC, UNITED STATES
Yoo, James, Winston Salem, NC, UNITED STATES
PA Wake Forest University Health Sciences, Winston-Salem, NC, UNITED STATES (U.S. corporation)
PI US 20090186065 A1 20090723
AI US 2009-356982 A1 20090121 (12)
PRAI US 2008-22028P 20080118 (61)
DT Utility
FS APPLICATION
LREP NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1620
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods and devices for isolating cells from a subject by circulating the subject's body fluid over an affinity moeity coupled matrix to isolate isolate cells from a subject either ex vivo or in vivo. One aspect of the invention is directed to connecting a subject to a system capable of circulating the subject's body fluid through an affinity moiety coupled matrix, such that the affinity moiety coupled matrix is capable of binding to and extracting target cells from the body fluid, and then eluting the target cells from the affinity moiety. Another aspect of the invention is directed to the apparatus for isolating cells from a subject, comprising a blood circulation system with an arterial side blood circuit for extracting blood and flowing the blood over an affinity moiety coupled matrix that binds to and extracts target cells and a venous side blood circuit for returning the blood to the patient. The invention is also directed to in vivo seeding of biomatrials by implanting the affinity moiety coupled matrix in a subject to attract and bind the target cells in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 75 USPATFULL on STN
AN 2009:144431 USPATFULL <<LOGINID::20111115>>
TI Methods, products and uses involving platelets and/or the vasculature
IN Munch, Gotz, Munchen, GERMANY, FEDERAL REPUBLIC OF
Bultmann, Andreas, Planegg, GERMANY, FEDERAL REPUBLIC OF
Boucher, Oliver Vimpany Arnold, London, UNITED KINGDOM
Chahwala, Suresh Babubhai, London, UNITED KINGDOM
Gawaz, Meinrad, Tubingen, GERMANY, FEDERAL REPUBLIC OF
Ungerer, Martin, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
PI US 20090130021 A1 20090521
AI US 2005-792857 A1 20051212 (11)
WO 2005-GB4764 20051212
20080401 PCT 371 date
RLI Continuation-in-part of Ser. No. US 2004-9106, filed on 10 Dec 2004, PENDING Continuation-in-part of Ser. No. US 2004-489053, filed on 24 Sep 2004, Pat. No. US 7514543 A 371 of International Ser. No. WO 2005-EP5929, filed on 5 Jun 2003

PRAI EP 2002-12742 20020607
EP 2005-256993 20051111
DT Utility
FS APPLICATION
LREP KLARQUIST SPARKMAN, LLP, 121 SW SALMON STREET, SUITE 1600, PORTLAND, OR, 97204, US
CLMN Number of Claims: 34
ECL Exemplary Claim: 1-88
DRWN 35 Drawing Page(s)
LN.CNT 7495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present disclosure relates to agents which interfere with the binding of GPVI to various components. Agents which interfere with GPVI interaction with one or both of fibronectin and vitronectin or sequences thereof are also disclosed. Methods of treating disorders or diseases which involve pathological, dysfunctional or non-pathological interaction of GPVI with fibronectin and/or vitronectin are included in the present disclosure. The invention also relates to uses of agents for the prevention or treatment of disorders arising from blood platelet adhesion and aggregation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 75 USPATFULL on STN
AN 2008:363095 USPATFULL <<LOGINID::20111115>>
TI Materials, Methods, and Systems for Cavitation-mediated Ultrasonic Drug Delivery in vivo
IN Hardy, Charles Thomas, Foster City, CA, UNITED STATES
PA Biovaluation & Analysis, Inc. (U.S. corporation)
PI US 20080319375 A1 20081225
AI US 2008-135130 A1 20080606 (12)
PRAI US 2007-943603P 20070613 (60)
US 2007-943589P 20070613 (60)
US 2007-943584P 20070613 (60)
US 2007-943574P 20070613 (60)
US 2007-942453P 20070606 (60)
US 2007-942451P 20070606 (60)
US 2007-942447P 20070606 (60)
US 2007-942443P 20070606 (60)
US 2007-942438P 20070606 (60)
DT Utility
FS APPLICATION
LREP Biovaluation & Analysis, Inc., 509 Jibstay Lane, Foster City, CA, 94404,
US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 30 Drawing Page(s)
LN.CNT 8585
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Materials, methods, and systems for targeted and non-targeted therapeutic delivery in vivo utilizing cavitation-mediated ultrasonic drug delivery are described. Noninvasive sonic energy being applied to the patient in a controlled fashion at the treatment area results in controlled acoustic cavitation at said region, and cell and tissue specific drug delivery. Microbubbles, both in the form of contrast agents, and/or other active agents infused into the patient, and/or bubbles formed from previous ultrasound exposure, allow for predictable cavitation thresholds, requiring much lower incident ultrasound intensities for permeating tissue. Further, methods and systems are provided that result in more spatially regular areas of controlled

tissue permeability upon treatment, limiting cytotoxicity and sonolysis, and maximizing intracellular drug delivery. Moreover, by using pulsed cavitation-mediated ultrasonic drug delivery as described by the present teachings, a large number of parameters are created, which provided the appropriate monitoring and feedback mechanisms are present, allow the use of a diversity of parameter optimizations and control systems for customizing the methods and systems for a given application. Preferred therapeutics for use with the present invention include nucleic acids, proteins, peptides, and other therapeutic macromolecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 75 USPATFULL on STN
AN 2008:355485 USPATFULL <<LOGINID::20111115>>
TI Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use
IN Daniloff, George Y., Mountain View, CA, UNITED STATES
Ngo, Michael Huy, Santa Clara, CA, UNITED STATES
Trollsas, Olof Mikael, San Jose, CA, UNITED STATES
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
PA Angiotech Pharmaceuticals(US),Inc., North Bend, WA, UNITED STATES (U.S. corporation)
PI US 20080312315 A1 20081218
AI US 2005-575484 A1 20050919 (11)
WO 2005-US33367 20050919
20070316 PCT 371 date
PRAI US 2004-611077P 20040917 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1-379
DRWN 2 Drawing Page(s)
LN.CNT 8005
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 75 USPATFULL on STN
AN 2007:342045 USPATFULL <<LOGINID::20111115>>
TI Anti-scarring drug combinations and use thereof
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA

Grau, Daniel S., Arlington, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES
PI US 20070299043 A1 20071227
AI US 2007-732808 A1 20070404 (11)
RLI Continuation-in-part of Ser. No. US 2006-542185, filed on 3 Oct 2006, PENDING
PRAI US 2005-723053P 20051003 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 37332
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 75 USPATFULL on STN
AN 2007:237758 USPATFULL <<LOGINID::20111115>>
TI Anti-scarring drug combinations and use thereof
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES
PI US 20070208134 A1 20070906
AI US 2006-542185 A1 20061003 (11)
PRAI US 2005-723053P 20051003 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 37771
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug

combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 75 USPATFULL on STN
AN 2007:225962 USPATFULL <<LOGINID::20111115>>
TI Electrical devices and anti-scarring drug combinations
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES
PI US 20070198063 A1 20070823
AI US 2006-542163 A1 20061003 (11)
PRAI US 2005-723637P 20051003 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 24469
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring drug combination or a composition that comprises an anti-scarring drug combination to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L11 ANSWER 18 OF 75 USPATFULL on STN
AN 2007:225856 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors, implantable pumps and anti-scarring drug combinations
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES
PI US 20070197957 A1 20070823
AI US 2006-542101 A1 20061003 (11)
PRAI US 2005-723638P 20051003 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 24410

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent or a composition that comprises an anti-scarring agent to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 75 USPATFULL on STN
AN 2007:224324 USPATFULL <<LOGINID::20111115>>
TI Soft tissue implants and drug combination compositions, and use thereof
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES
PI US 20070196421 A1 20070823
AI US 2006-542211 A1 20061003 (11)
PRAI US 2005-723601P 20051003 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 22161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 20 OF 75 USPATFULL on STN
AN 2007:204460 USPATFULL <<LOGINID::20111115>>
TI Injectable crosslinked and uncrosslinked alginates and the use thereof in medicine and in cosmetic surgery
IN Reiner, Roland, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Geigle, Peter, Alzenau, GERMANY, FEDERAL REPUBLIC OF
Glockner, Herma, Kleinwallstadt, GERMANY, FEDERAL REPUBLIC OF
Thurmer, Frank, Alzenau, GERMANY, FEDERAL REPUBLIC OF
PI US 20070179117 A1 20070802
AI US 2005-599980 A1 20050302 (10)
WO 2005-EP2201 20050302
20070403 PCT 371 date
PRAI DE 2004-102004019241 20040416
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1-22
DRWN No Drawings
LN.CNT 647
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of implantable microcapsules, or microparticles or gels produced from alginates that are crosslinked with bivalent or multivalent cations or that are uncrosslinked, for the treatment of skin defects such as e.g. wrinkles, for the treatment of gastro-oesophageal reflux, urinary incontinence and vesico-ureteral reflux.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 75 USPATFULL on STN
AN 2007:154033 USPATFULL <<LOGINID::20111115>>
TI Rankl antibody-PTH/PTHrP chimeric molecules
IN Kostenuik, Paul, Newbury Park, CA, UNITED STATES
Shen, Wenyan, Palo Alto, CA, UNITED STATES
Boone, Thomas C., Newbury Park, CA, UNITED STATES
PI US 20070134245 A1 20070614
AI US 2006-599629 A1 20061113 (11)
PRAI US 2005-736664P 20051114 (60)
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
CLMN Number of Claims: 68
ECL Exemplary Claim: 1
DRWN 29 Drawing Page(s)
LN.CNT 7353
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chimeric molecules comprising receptor activator of NF-κB ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 75 USPATFULL on STN
AN 2006:328918 USPATFULL <<LOGINID::20111115>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20060282123 A1 20061214
AI US 2004-6910 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2264

DRWN 32 Drawing Page(s)
LN.CNT 14774
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L11 ANSWER 23 OF 75 USPATFULL on STN
AN 2006:301023 USPATFULL <<LOGINID::20111115>>
TI Production of tissue engineered digits and limbs
IN Atala, Anthony, Winston-Salem, NC, UNITED STATES
Yoo, James J., Winston-Salem, NC, UNITED STATES
Lim, Grace, Winston-Salem, NC, UNITED STATES
Lee, Sang Jin, Winston-Salem, NC, UNITED STATES
PA Wake Forest University Health Services, Winston-Salem, NC, UNITED STATES (U.S. corporation)
PI US 20060257377 A1 20061116
AI US 2006-373046 A1 20060310 (11)
PRAI US 2005-660832P 20050311 (60)
US 2005-663458P 20050318 (60)
DT Utility
FS APPLICATION
LREP NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER
WEST, 155 SEAPORT
BOULEVARD, BOSTON, MA, 02210-2604, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 3429
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention pertains to methods of producing artificial composite tissue constructs that permit coordinated motion. Biocompatable structural matrices having sufficient rigidity to provide structural support for cartilage-forming cells and bone-forming cells are used. Biocompatable flexible matrices seeded with muscle cells are joined to the structural matrices to produce artificial composite tissue constructs that are capable of coordinated motion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 75 USPATFULL on STN
AN 2006:296022 USPATFULL <<LOGINID::20111115>>
TI Production of tissue engineered heart valves
IN Atala, Anthony, Winston Salem, NC, UNITED STATES
Yoo, James J., Winston Salem, NC, UNITED STATES
PA Wake Forest University Health Sciences, Winston-Salem, NC, UNITED STATES (U.S. corporation)
PI US 20060253192 A1 20061109
AI US 2006-373066 A1 20060310 (11)
PRAI US 2005-660832P 20050311 (60)
US 2005-686316P 20050601 (60)
DT Utility
FS APPLICATION
LREP NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER
WEST, 155 SEAPORT
BOULEVARD, BOSTON, MA, 02210-2604, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)

LN.CNT 3335
AB The invention is directed to methods for preparing artificial heart valves by preconditioning a matrix seeded with endothelial cells and smooth muscle cells differentiated from isolated progenitor cells. These cell seeded matrices are exposed to fluid conditions that mimic blood flow through the heart to produce tissue engineered heart valves that are analogous to native heart valves.

L11 ANSWER 25 OF 75 USPATFULL on STN
AN 2006:281123 USPATFULL <<LOGINID::20111115>>
TI Tissue engineered blood vessels
IN Atala, Anthony, Winston Salem, NC, UNITED STATES
Soker, Shay, Greensboro, NC, UNITED STATES
Yoo, James J., Winston Salem, NC, UNITED STATES
PA Wake Forest University Health Services, Winston-Salem, NC, UNITED STATES (U.S. corporation)
PI US 20060240061 A1 20061026
AI US 2006-372743 A1 20060310 (11)
PRAI US 2005-660832P 20050311 (60)
US 2005-664212P 20050321 (60)
DT Utility
FS APPLICATION
LREP NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 3183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to methods for preparing artificial blood vessels by preconditioning a matrix seeded with endothelial cells to fluid flow conditions that mimic blood flow.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 26 OF 75 USPATFULL on STN
AN 2006:240094 USPATFULL <<LOGINID::20111115>>
TI Electrospun cell matrices
IN Atala, Anthony, Winston Salem, NC, UNITED STATES
Yoo, James, Winston Salem, NC, UNITED STATES
Lim, Grace, Winston-Salem, NC, UNITED STATES
Czerw, Richard, Clemmons, NC, UNITED STATES
Soker, Shay, Greensboro, NC, UNITED STATES
Stitzel, Joel, Winston-Salem, NC, UNITED STATES
PI US 20060204539 A1 20060914
AI US 2005-83853 A1 20050318 (11)
PRAI US 2005-660832P 20050311 (60)
DT Utility
FS APPLICATION
LREP NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 2598
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to compositions and methods for preparing electrospun matrices comprising at least one natural biological material

component and at least one synthetic polymer material. The natural component makes the matrices highly biocompatible while the molecular weight polymer component can impart additional strength mechanical strength to the scaffold and/or improve ease of manufacture by increasing viscosity and spinning characteristics of the solution during electrospining.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 27 OF 75 USPATFULL on STN
AN 2006:240000 USPATFULL <<LOGINID::20111115>>
TI Cell scaffold matrices with image contrast agents
IN Atala, Anthony, Winston Salem, NC, UNITED STATES
Soker, Shay, Greensboro, NC, UNITED STATES
Yoo, James, Winston Salem, NC, UNITED STATES
Stitzel, Joel, Winston-Salem, NC, UNITED STATES
Czerw, Richard, Clemmons, NC, UNITED STATES
Lim, Grace, Winston-Salem, NC, UNITED STATES
PI US 20060204445 A1 20060914
AI US 2005-83602 A1 20050318 (11)
PRAI US 2005-660832P 20050311 (60)
DT Utility
FS APPLICATION
LREP NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER
WEST, 155 SEAPORT
BOULEVARD, BOSTON, MA, 02210-2604, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 2578
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to methods and compositions for monitoring remodeling of an artificial tissue construct using image or contrast enhancing agents. The invention allows the growth, development, and remodeling of the artificial tissue to be monitored.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 28 OF 75 USPATFULL on STN
AN 2006:239996 USPATFULL <<LOGINID::20111115>>
TI Cell scaffold matrices with incorporated therapeutic agents
IN Atala, Anthony, Winston Salem, NC, UNITED STATES
Yoo, James, Winston Salem, NC, UNITED STATES
Lim, Grace, Winston-Salem, NC, UNITED STATES
Czerw, Richard, Clemmons, NC, UNITED STATES
Soker, Shay, Greensboro, NC, UNITED STATES
Stitzel, Joel, Winston-Salem, NC, UNITED STATES
PI US 20060204441 A1 20060914
US 7531503 B2 20090512
AI US 2005-84350 A1 20050318 (11)
PRAI US 2005-660832P 20050311 (60)
DT Utility
FS APPLICATION
LREP NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER
WEST, 155 SEAPORT
BOULEVARD, BOSTON, MA, 02210-2604, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 2662
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to methods and compositions for preparing matrices for controlled delivery of at least one therapeutic or biological agent to a target site in a subject. This is accomplished using nanoparticles coupled to the therapeutic or biological agent that are incorporated within the matrix or reacted on the surface of the matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 29 OF 75 USPATFULL on STN
AN 2005:323977 USPATFULL <<LOGINID::20111115>>
TI Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
IN Daniloff, George Y., Mountain View, CA, UNITED STATES
Sehl, Louis C., Redwood City, CA, UNITED STATES
Trollsas, Olof Mikael, San Jose, CA, UNITED STATES
Schroeder, Jacqueline, Boulder Creek, CA, UNITED STATES
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
PI US 20050281883 A1 20051222
AI US 2005-118088 A1 20050428 (11)
PRAI US 2004-566569P 20040428 (60)
DT Utility
FS APPLICATION
LREP REED INTELLECTUAL PROPERTY LAW GROUP, 1400 PAGE MILL ROAD, PALO ALTO, CA, 94304-1124, US
CLMN Number of Claims: 349
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 8347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Crosslinkable compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. In one embodiment, a first component has nucleophilic groups and a second component has electrophilic groups. Additional components may have nucleophilic or electrophilic groups. Methods for preparing and using the compositions are also provided as are kits for delivery of the compositions. Exemplary uses for the crosslinked compositions include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 30 OF 75 USPATFULL on STN
AN 2005:241661 USPATFULL <<LOGINID::20111115>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050209666 A1 20050922
AI US 2004-6885 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)

```
       US 2004-578471P         20040609 (60)
       US 2003-526541P         20031203 (60)
       US 2003-525226P         20031124 (60)
       US 2003-523908P         20031120 (60)
       US 2003-524023P         20031120 (60)
DT     Utility
FS     APPLICATION
LREP   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
       6300, SEATTLE, WA, 98104-7092, US
CLMN   Number of Claims: 112
ECL    Exemplary Claim: 1-630
DRWN   32 Drawing Page(s)
LN.CNT 14772
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Electrical devices (e.g., cardiac rhythm management and neurostimulation
       devices) for contact with tissue are used in combination with an
       anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit
       scarring that may otherwise occur when the devices are implanted within
       an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 31 OF 75  USPATFULL on STN
AN     2005:241660  USPATFULL <<LOGINID::20111115>>
TI     Electrical devices and anti-scarring agents
IN     Hunter, William L., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
PA     Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI     US 20050209665      A1  20050922
AI     US 2004-998351      A1  20041126 (10)
RLI    Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING
       Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004,
       PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov
       2004, PENDING
PRAI   US 2004-586861P         20040709 (60)
       US 2004-578471P         20040609 (60)
       US 2003-526541P         20031203 (60)
       US 2003-525226P         20031124 (60)
       US 2003-523908P         20031120 (60)
       US 2003-524023P         20031120 (60)
DT     Utility
FS     APPLICATION
LREP   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
       6300, SEATTLE, WA, 98104-7092, US
CLMN   Number of Claims: 112
ECL    Exemplary Claim: 1-11691
DRWN   32 Drawing Page(s)
LN.CNT 14777
AB     Electrical devices (e.g., cardiac rhythm management and neurostimulation
       devices) for contact with tissue are used in combination with an
       anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit
       scarring that may otherwise occur when the devices are implanted within
       an animal.


L11  ANSWER 32 OF 75  USPATFULL on STN
AN     2005:241659  USPATFULL <<LOGINID::20111115>>
TI     Electrical devices and anti-scarring agents
IN     Hunter, William L., Vancouver, CANADA
```

Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050209664 A1 20050922
AI US 2004-998349 A1 20041126 (10)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586471P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1377
DRWN 32 Drawing Page(s)
LN.CNT 14786
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L11 ANSWER 33 OF 75 USPATFULL on STN
AN 2005:240095 USPATFULL <<LOGINID::20111115>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050208095 A1 20050922
AI US 2004-996354 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 34089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 34 OF 75 USPATFULL on STN
AN 2005:234693 USPATFULL <<LOGINID::20111115>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050203635 A1 20050915
AI US 2004-6909 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 76
ECL Exemplary Claim: 1-3038
DRWN 32 Drawing Page(s)
LN.CNT 12596
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 35 OF 75 USPATFULL on STN
AN 2005:226572 USPATFULL <<LOGINID::20111115>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050196421 A1 20050908
AI US 2004-1417 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 100
ECL Exemplary Claim: 1-7300
DRWN 32 Drawing Page(s)
LN.CNT 34222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 36 OF 75 USPATFULL on STN
AN 2005:221910 USPATFULL <<LOGINID::20111115>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050192647 A1 20050901
AI US 2004-6898 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1992
DRWN 32 Drawing Page(s)
LN.CNT 14794
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L11 ANSWER 37 OF 75 USPATFULL on STN
AN 2005:215962 USPATFULL <<LOGINID::20111115>>
TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050187639 A1 20050825
AI US 2004-6892 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1-3470
DRWN 32 Drawing Page(s)
LN.CNT 12657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 38 OF 75 USPATFULL on STN
AN 2005:215923 USPATFULL <<LOGINID::20111115>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050187600 A1 20050825
AI US 2004-998350 A1 20041126 (10)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-3352

DRWN 32 Drawing Page(s)
LN.CNT 14781
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L11 ANSWER 39 OF 75 USPATFULL on STN
AN 2005:215464 USPATFULL <<LOGINID::20111115>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050187140 A1 20050825
AI US 2004-408 A1 20041129 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2004-611077P 20040917 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 103
ECL Exemplary Claim: 1-5846
DRWN 32 Drawing Page(s)
LN.CNT 34103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 40 OF 75 USPATFULL on STN
AN 2005:214574 USPATFULL <<LOGINID::20111115>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050186246 A1 20050825
AI US 2004-6883 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1-2606
DRWN 32 Drawing Page(s)
LN.CNT 12658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 41 OF 75 USPATFULL on STN
AN 2005:214573 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050186245 A1 20050825
AI US 2004-6880 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2785
DRWN 32 Drawing Page(s)
LN.CNT 15059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 42 OF 75 USPATFULL on STN

AN 2005:214572 USPATFULL <<LOGINID::20111115>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050186244 A1 20050825
AI US 2004-1790 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 103
ECL Exemplary Claim: 1-8540
DRWN 32 Drawing Page(s)
LN.CNT 34060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 43 OF 75 USPATFULL on STN
AN 2005:214567 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050186239 A1 20050825
AI US 2004-6897 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-3058
DRWN 32 Drawing Page(s)
LN.CNT 15050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 44 OF 75 USPATFULL on STN
AN 2005:212068 USPATFULL <<LOGINID::20111115>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050183731 A1 20050825
AI US 2004-6908 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1-8061
DRWN 32 Drawing Page(s)
LN.CNT 34032
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L11 ANSWER 45 OF 75 USPATFULL on STN
AN 2005:210011 USPATFULL <<LOGINID::20111115>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182496 A1 20050818

AI US 2004-6906 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 76
ECL Exemplary Claim: 1-3902
DRWN 32 Drawing Page(s)
LN.CNT 12588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 46 OF 75 USPATFULL on STN
AN 2005:209984 USPATFULL <<LOGINID::20111115>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050182469 A1 20050818
AI US 2004-7837 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 120
ECL Exemplary Claim: 1-2803
DRWN 32 Drawing Page(s)
LN.CNT 14838
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within

an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 47 OF 75 USPATFULL on STN
AN 2005:209983 USPATFULL <<LOGINID::20111115>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182468 A1 20050818
AI US 2004-6891 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1720
DRWN 32 Drawing Page(s)
LN.CNT 14768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 48 OF 75 USPATFULL on STN
AN 2005:209982 USPATFULL <<LOGINID::20111115>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182467 A1 20050818
AI US 2004-6884 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1168
DRWN 32 Drawing Page(s)
LN.CNT 14785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 49 OF 75 USPATFULL on STN
AN 2005:209978 USPATFULL <<LOGINID::20111115>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050182463 A1 20050818
AI US 2004-1788 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 125
ECL Exemplary Claim: 1-8059
DRWN 32 Drawing Page(s)
LN.CNT 34070
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L11 ANSWER 50 OF 75 USPATFULL on STN
AN 2005:209965 USPATFULL <<LOGINID::20111115>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182450 A1 20050818
AI US 2004-6890 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-349
DRWN 32 Drawing Page(s)
LN.CNT 14792
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L11 ANSWER 51 OF 75 USPATFULL on STN
AN 2005:208532 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181010 A1 20050818
AI US 2004-1789 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 109
ECL Exemplary Claim: 1-296
DRWN 32 Drawing Page(s)
LN.CNT 15014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to

inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 52 OF 75 USPATFULL on STN
AN 2005:208531 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181009 A1 20050818
AI US 2004-1787 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 110
ECL Exemplary Claim: 1-570
DRWN 32 Drawing Page(s)
LN.CNT 15035
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 53 OF 75 USPATFULL on STN
AN 2005:208529 USPATFULL <<LOGINID::20111115>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181007 A1 20050818
AI US 2004-1415 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 126
ECL Exemplary Claim: 1-444
DRWN 32 Drawing Page(s)
LN.CNT 12675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 54 OF 75 USPATFULL on STN
AN 2005:208527 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050181005 A1 20050818
AI US 2004-6901 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2510
DRWN 32 Drawing Page(s)
LN.CNT 15035
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 55 OF 75 USPATFULL on STN
AN 2005:205930 USPATFULL <<LOGINID::20111115>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050178396 A1 20050818
AI US 2004-6905 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1-8063
DRWN 32 Drawing Page(s)
LN.CNT 33965
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L11 ANSWER 56 OF 75 USPATFULL on STN
AN 2005:205929 USPATFULL <<LOGINID::20111115>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050178395 A1 20050818
AI US 2004-6900 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 58
ECL Exemplary Claim: 1-7302
DRWN 32 Drawing Page(s)
LN.CNT 34043

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L11 ANSWER 57 OF 75 USPATFULL on STN
AN 2005:202285 USPATFULL <<LOGINID::20111115>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050175703 A1 20050811
AI US 2004-6888 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1-7576
DRWN 32 Drawing Page(s)
LN.CNT 33992
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 58 OF 75 USPATFULL on STN
AN 2005:202247 USPATFULL <<LOGINID::20111115>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050175665 A1 20050811
AI US 2004-6896 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1-7822
DRWN 32 Drawing Page(s)
LN.CNT 33978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 59 OF 75 USPATFULL on STN
AN 2005:202246 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050175664 A1 20050811
AI US 2004-4672 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 109
ECL Exemplary Claim: 1-851
DRWN 32 Drawing Page(s)
LN.CNT 15038
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 60 OF 75 USPATFULL on STN
AN 2005:195820 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050169961 A1 20050804
AI US 2004-4675 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 118
ECL Exemplary Claim: 1-1941
DRWN 32 Drawing Page(s)
LN.CNT 15063
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 61 OF 75 USPATFULL on STN
AN 2005:195819 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050169960 A1 20050804
AI US 2004-4671 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 110
ECL Exemplary Claim: 1-3328
DRWN 32 Drawing Page(s)
LN.CNT 15057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 62 OF 75 USPATFULL on STN
AN 2005:182973 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050158356 A1 20050721
AI US 2004-996352 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 117
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 15058
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 63 OF 75 USPATFULL on STN
AN 2005:178293 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vacouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050154374 A1 20050714
AI US 2004-6882 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov

2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2240
DRWN 32 Drawing Page(s)
LN.CNT 15052
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 64 OF 75 USPATFULL on STN
AN 2005:176868 USPATFULL <<LOGINID::20111115>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152948 A1 20050714
AI US 2004-7838 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-2174
DRWN 32 Drawing Page(s)
LN.CNT 12627
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 65 OF 75 USPATFULL on STN
AN 2005:176867 USPATFULL <<LOGINID::20111115>>

TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152947 A1 20050714
AI US 2004-6903 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-1742
DRWN 32 Drawing Page(s)
LN.CNT 12637
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 66 OF 75 USPATFULL on STN
AN 2005:176866 USPATFULL <<LOGINID::20111115>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152946 A1 20050714
AI US 2004-6894 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1126
DRWN 32 Drawing Page(s)

LN.CNT 15056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 67 OF 75 USPATFULL on STN
AN 2005:176865 USPATFULL <<LOGINID::20111115>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152945 A1 20050714
AI US 2004-6887 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-1310
DRWN 32 Drawing Page(s)
LN.CNT 12592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 68 OF 75 USPATFULL on STN
AN 2005:176864 USPATFULL <<LOGINID::20111115>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152944 A1 20050714
AI US 2004-6881 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-878
DRWN 32 Drawing Page(s)
LN.CNT 12628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 69 OF 75 USPATFULL on STN
AN 2005:176861 USPATFULL <<LOGINID::20111115>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152941 A1 20050714
AI US 2004-996353 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 132
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 12685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 70 OF 75 USPATFULL on STN
AN 2005:172408 USPATFULL <<LOGINID::20111115>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050149157 A1 20050707
AI US 2004-996355 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 111
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 14769
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 71 OF 75 USPATFULL on STN
AN 2005:164738 USPATFULL <<LOGINID::20111115>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050142162 A1 20050630
AI US 2004-1416 A1 20041201 (11)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-524023P 20031120 (60)
US 2003-523908P 20031120 (60)
US 2003-525226P 20031124 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 117
ECL Exemplary Claim: 1-4334
DRWN 32 Drawing Page(s)
LN.CNT 12679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is

placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 72 OF 75 USPATFULL on STN
AN 2005:62607 USPATFULL <<LOGINID::20111115>>
TI Biocompatible materials
IN Ulbricht, Mathias, Berlin, GERMANY, FEDERAL REPUBLIC OF
Thom, Volkmar, Arlington, MA, UNITED STATES
Jankova, Katja, Burgas, BULGARIA
Altankov, George, Sofia, BULGARIA
Jonsson, Gunnar, Vaerloese, DENMARK
PI US 20050053642 A1 20050310
AI US 2003-362677 A1 20030815 (10)
WO 2001-DK557 20010823
PRAI DK 2000-1250 20000823
DT Utility
FS APPLICATION
LREP Browdy and Neimark, Suite 300, 624 Ninth Street NW, Washington, DC, 20001
CLMN Number of Claims: 125
ECL Exemplary Claim: 1
DRWN 31 Drawing Page(s)
LN.CNT 6442
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention teaches a novel approach of creating biocmpatible surfaces, said surfaces being capable of functionally interact with biological material. SAid biocompatible surfaces comrise at least two comonents, such as a hydrophobic substratum and a macromolecule of hydrophilic nature, which, in a cooperativity, form together the novel biocoompatible surfaces. The novel approach is ased on contacting said hydrophobic substratum with a laterally patterned monomolecular layer of said hydrophilic and flexible macromolecules, exhibiting a pronounced excluded volume. The htus formed two component surface is, in respect to polarity and morphology, a molecularly heterogeneous surface. Structural features of said macromolecular monolayer (as e.g. the layer thickness or its lateral density) are determined by: i) the structural features of the layer forming macromolecules (as e.g. their MW or their molecular architecture) and ii) the method of creating said monomolecular layer (as e.g. by physi- or chemisorbing, or by chemically binding said macromolecules). The structural features of the layer forming macromolecules(s) is in turn determined by synthesis. AMount and conformation and thus also biological activity of biological material (as e.g. polypeptides) which contact the novel biocompatible surface, is determined and maintained by the cooperative action of the underlying hydrophobic substratum and the macromolecular layer. In this way it becomes possible to maintain and control biological interactions between said contacted polypeptides and other biological compounds as e.g. cells, antibodies and the like. Consequently, the present invention aims to reduce and/or eliminate the deactivation and/or denaturation associated with the contacting of polypeptides and/or other biological material to a hydrophobic substratum surface.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 73 OF 75 USPATFULL on STN
AN 2005:3813 USPATFULL <<LOGINID::20111115>>
TI Enhancement of angiogenesis to grafts using cells engineered to produce growth factors
IN Atala, Anthony, Winston Salem, NC, UNITED STATES
Stoker, Shay, Greensboro, NC, UNITED STATES

PI US 20050002915 A1 20050106
AI US 2004-766642 A1 20040128 (10)
PRAI US 2003-443129P 20030128 (60)
DT Utility
FS APPLICATION
LREP NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 4126
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods and compositions of engineered cells for use in the continuous or transient delivery of growth factors and angiogenesis modulating agents, such as vascular endothelial growth factor (VEGF), in conjunction with constructs for replacing or augmenting organ functions. In one aspect of he invention, the genetically engineered cells can be immature cells that are capable of differentiating and assimilating into the target region. The methods of the present invention can be used to enhance vascularization locally at a target site in need of repair, growth, or implantation through the incorporation of autologous cells which have been genetically engineered to secrete a growth factor or angiogenesis modulating agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 74 OF 75 USPATFULL on STN
AN 2004:279914 USPATFULL <<LOGINID::20111115>>
TI Tissue reactive compounds and compositions and uses thereof
IN Gravett, David M., Vancouver, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Embree, Leanne, Squamish, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20040219214 A1 20041104
AI US 2003-749123 A1 20031230 (10)
PRAI US 2003-440924P 20030117 (60)
US 2002-437384P 20021230 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 240
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 5170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition comprising a synthetic polymer, optionally in the presence of a drug, where the polymer comprises multiple activated groups. The multiple activated groups are reactive with functionality present on animal tissue, so that upon administration of the polymer to the tissue, the polymer binds to the tissue. Alternatively, the multiple activated groups are reactive with functionality present on a non-living surface, where the polymer binds to this surface to, e.g., increase the lubricity of the surface. When drug is present in the composition, the drug is then delivered to the site of polymer attachment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 75 OF 75 USPAT2 on STN
AN 2006:239996 USPAT2 <<LOGINID::20111115>>
TI Cell scaffold matrices with incorporated therapeutic agents
IN Atala, Anthony, Winston Salem, NC, UNITED STATES
Yoo, James, Winston Salem, NC, UNITED STATES
Lim, Grace, Winston-Salem, NC, UNITED STATES
Czerw, Richard, Clemmons, NC, UNITED STATES
Soker, Shay, Greensboro, NC, UNITED STATES
Stitzel, Joel, Winston-Salem, NC, UNITED STATES
PA Wake Forest University Health Sciences, Winston-Salem, NC, UNITED STATES
(U.S. corporation)
PI US 7531503 B2 20090512
AI US 2005-84350 20050318 (11)
PRAI US 2005-660832P 20050311 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Henley, III, Raymond J
LREP Engellenner, Thomas J., Morgan, Kelly J., Nutter McClennen
& Fish LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to methods and compositions for preparing matrices for controlled delivery of at least one therapeutic or biological agent to a target site in a subject. This is accomplished using nanoparticles coupled to the therapeutic or biological agent that are incorporated within the matrix or reacted on the surface of the matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis hist

(FILE 'HOME' ENTERED AT 10:44:17 ON 15 NOV 2011)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT, NTIS, PASCAL, RAPRA, SCISEARCH, USPATFULL, USPATOLD, USPAT2, WPINDEX, WSCA, MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:44:35 ON 15 NOV 2011
L1 235563 S ALGINATE
L2 35069 S L1 AND CROSSLINK?
L3 24186 S L2 AND (BARIUM OR CALCIUM)
L4 14887 S L3 AND (MOLECULAR (A) WEIGHT)
L5 3112 S L4 AND KDA
L6 142 S L5 AND ((TISSUE(A)VOLUME) OR (TISSUE(A)AUGMENT?))
L7 139 S L6 AND (SKIN OR MUSCLE OR SPHINCTER OR BLADDER)
L8 138 S L7 AND (GEL OR MICROPARTICLES)
L9 131 S L8 AND BUFFER
L10 94 S L9 AND CITRATE
L11 75 S L10 AND EDTA

=>